

STIC-ILL

105

104/26

From: Yaen, Christopher  
Sent: Thursday, April 25, 2002 5:46 PM  
T: STIC-ILL  
Subject: 09815306

Rm 270. J6

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

392 925

11696695

Christopher Yaen  
Patent Examiner  
Art Unit 1642  
CM1-Rm 8E18  
Mail Box 8E12  
703-305-3586

Scientific and Technical  
Information Center

APR 29 RECD

PAT. & T.M. OFFICE

672 7586

Scientific and Technical  
Information Center

RECD

PAT. & T.M. OFFICE

STIC-ILL

NOV 4/26

From: Yaen, Christopher  
Sent: Thursday, April 25, 2002 5:46 PM  
T: STIC-ILL  
Subject: 09815306

392901

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

11708720

Christopher Yaen  
Patent Examiner  
Art Unit 1642  
CM1-Rm 8E18  
Mail Box 8E12  
703-305-3586

6721091

Scientific and Technical  
Information Center

APR 26 RECD

PAT. & T.M. OFFICE

STIC-ILL

*NPL*

**From:** Yaen, Christopher  
**Sent:** Thursday, April 25, 2002 5:46 PM  
**To:** STIC-ILL  
**Subject:** 09815306

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

Christopher Yaen  
Patent Examiner  
Art Unit 1642  
CM1-Rm 8E18  
Mail Box 8E12  
703-305-3586

STIC-ILL

NPL

**From:** Yaen, Christopher  
**Sent:** Thursday, April 25, 2002 5:46 PM  
**To:** STIC-ILL  
**Subject:** 09815306

could you get these references:

1. Macieira-Coelho A Biogerontology 2001;2(3):179-92
2. Mocellin S et al. J Immunother 2001 Sep-Oct;24(5):392-407
3. Penichet ML et al J Immunol Methods 2001 Feb 1;248(1-2):91-101
4. Mittra I, Naresh KN. Lancet 1997 Dec 20-27;350 Suppl 3:SIII17

Christopher Yaen  
Patent Examiner  
Art Unit 1642  
CM1-Rm 8E18  
Mail Box 8E12  
703-305-3586

FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002

=> file medline, cancerlit, caplus, embase, biosis, uspatfull  
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL  
FULL ESTIMATED COST 0.21 SESSION 0.21

FILE 'MEDLINE' ENTERED AT 10:34:58 ON 25 APR 2002

FILE 'CANCERLIT' ENTERED AT 10:34:58 ON 25 APR 2002

FILE 'CAPLUS' ENTERED AT 10:34:58 ON 25 APR 2002  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:34:58 ON 25 APR 2002  
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:34:58 ON 25 APR 2002  
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'USPATFULL' ENTERED AT 10:34:58 ON 25 APR 2002  
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fusion protein? or chimera?  
L1 4 FILES SEARCHED...  
246870 FUSION PROTEIN? OR CHIMERA?

=> s il2 or interleukin 2 and il1  
L2 17094 IL2 OR INTERLEUKIN 2 AND IL1

=> s il1 and interleukin 12 or il 12  
L3 27059 IL1 AND INTERLEUKIN 12 OR IL 12

=> s il1 and interferon gamma or gamma interferon or ifn  
L4 208008 IL1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN

=> s prolactin agonist  
L5 10 PROLACTIN AGONIST

=> s prolactin antagonist  
L6 80 PROLACTIN ANTAGONIST

=> s 16 not py=>2000  
L7 55 L6 NOT PY=>2000

=> dup rem l7  
PROCESSING COMPLETED FOR L7  
L8 35 DUP REM L7 (20 DUPLICATES REMOVED)

=> d 18 1-35

L8 ANSWER 1 OF 35 MEDLINE DUPLICATE 1  
AN 2000055692  
DN 20055692 PubMed ID: 10589775  
TI A human prolactin antagonist, hPRL-G129R, inhibits  
breast cancer cell proliferation through induction of apoptosis.  
CM Erratum in: Clin Cancer Res 2000 May;6(5):2120  
AU Chen W Y; Ramamoorthy P; Chen N; Sticca R; Wagner T E  
CS Oncology Research Institute, Cancer Center, Greenville Hospital System,  
South Carolina 29605, USA. wchen@ghs.org  
SO CLINICAL CANCER RESEARCH. (1999 Nov) 5 (11) 3583-93.  
Journal code: CZH; 9502500. ISSN: 1078-0432.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 200001  
ED Entered STN: 20000114  
Last Updated on STN: 20000928  
Entered Medline: 20000106

L8 ANSWER 2 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1999:193009 BIOSIS  
DN PREV199900193009  
TI Inhibitory effects of a prolactin antagonist in human  
breast cancer cell proliferation and its synergistic action in conjunction  
with tamoxifen.  
AU Chen, W. Y. (1); Long, Y.; Ramamoorthy, P.; Wei, Y.; Sticca, R. P.;  
Wagner, T. E.  
CS (1) Oncol. Res. Div., Cancer Treatment Cent., Greenville Hosp. System,  
Clemson, SC 29634 USA  
SO Proceedings of the American Association for Cancer Research Annual  
Meeting, (March, 1999) Vol. 40, pp. 733.  
Meeting Info.: 90th Annual Meeting of the American Association for Cancer  
Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American  
Association for Cancer Research  
ISSN: 0197-016X.

DT Conference  
LA English

L8 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2002 ACS  
AN 1999:647558 CAPLUS  
DN 132:149813  
TI Prolactin involvement in breast cancer  
AU Vonderhaar, B. K.  
CS Molecular and Cellular Endocrinology Section, Laboratory of Tumor  
Immunology and Biology, National Cancer Institute, National Institutes of  
Health, Bethesda, MD, 20892-1402, USA  
SO Endocrine-Related Cancer (1999), 6 (3), 389-404  
CODEN: ERCAE9; ISSN: 1351-0088

PB Society for Endocrinology  
DT Journal; General Review  
LA English  
RE.CMT 158 THERE ARE 158 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2002 ACS  
AN 1998:356025 CAPLUS  
DN 129:118021  
TI Prolactin is an antagonist of TGF-beta activity and promotes  
proliferation of murine B cell hybridomas  
AU Richards, Susan M.; Garman, Richard D.; Keyes, Lynne; Kavanagh, Brian;  
McPherson, John M.  
CS Immunol. Lab., Dep. Cell Protein Therapeutics R & D, Genzyme Corp.,  
Framingham, MA, 01701-9322, USA  
SO Cell. Immunol. (1998), 184 (2), 85-91  
CODEN: CLIMB8; ISSN: 0008-8749  
PB Academic Press  
LA English

L8 ANSWER 5 OF 35 USPATFULL  
AN 37:5190 USPATFULL  
TI Compositions and methods for treating exocrine gland atrophy  
Kaswan, Renee, Athens, GA, United States  
Mitrcheff, Austin K., LaCrescenta, CA, United States

PA Warren, Dwight W., Granada Hills, CA, United States  
(U.S. corporation)  
University of Georgia Research Foundation, Athens, GA, United States  
University of Southern California, Los Angeles, CA, United States (U.S. corporation)

PI US 5639743 19970617  
US 1994-268971 19940630 (8)

AI Continuation of Ser. No. US 1992-975869, filed on 13 Nov 1992, now abandoned

DT Utility

FS Granted

LN.CNT 711

INCL INCLM: 514/171.000  
INCLM: 514/177.000; 514/250.000; 514/254.000; 514/410.000  
NCLM: 514/021.000  
NCLM: 514/002.000; 514/171.000; 514/177.000; 514/250.000; 514/410.000

IC ICH: A61K031-56  
ICS: A61K031-495; A61K031-50; A61K031-40  
EXF 514/250; 514/254; 514/177; 514/171; 514/410  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 35 MEDLINE  
AN 1998068083  
DN 98068083 PubMed ID: 9404272  
TI Termination of diestrus and induction of oestrus in dioestrous nonpregnant bitches by the **prolactin antagonist** cabergoline.

CS Jeukene P; Versteegen J  
AU Dept of Small Animal Reproduction, University of Liege, College of Veterinary Medicine Belgium  
SO JOURNAL OF REPRODUCTION AND FERTILITY SUPPLEMENT, (1997) 51 59-66.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199801  
ED Entered STN: 19980129  
Last Updated on STN: 19980129  
Entered Medline: 19980109

L8 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2002 ACS  
AN 1996:423995 CAPLUS  
DN 125:105329  
TI Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay

AU Goffin, Vincent; Kinet, Sandrine; Ferrag, Fatima; Binart, Nadine; Martial, Joseph A.; Kelly, Paul A.  
CS Endocrinol. Mol., INSERM, Paris, 75730, Fr.  
SO J. Biol. Chem. (1996), 271(28), 16573-16579  
CODEN: JBCHA3; ISSN: 0021-9258

DT Journal  
LA English

L8 ANSWER 8 OF 35 MEDLINE  
AN 95259840  
DN 95259840 PubMed ID: 7741273  
TI Disturbance of follicular development and endocrine reactions induced by the antiovarian effective progesterone antagonist Onapristone.

AU Schubert C; Nishino Y; Michna H  
CS Forschungslaboratorien der Schering AG Berlin, Germany.  
SO ANATOMISCHER ANZEIGER, (1995 Mar) 177 (2) 139-46.  
Journal code: APE; 0370541. ISSN: 0003-2786.

CY GERMANY: Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199506  
ED Entered STN: 19950615  
Last Updated on STN: 19990129  
Entered Medline: 19950602

L8 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2002 ACS  
AN 1993:183694 CAPLUS  
DN 118:183694  
TI Mechanism-based design of prolactin receptor antagonists

AU Fuh, Germaine; Colosi, Peter; Wood, William I.; Wells, James A.  
CS Dep. Protein Eng., Genentech, Inc., South San Francisco, CA, 94080-4990, USA  
SO J. Biol. Chem. (1993), 268(8), 5376-81  
CODEN: JBCHA3; ISSN: 0021-9258

DT Journal  
LA English

L8 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2002 ACS  
AN 1992:233518 CAPLUS  
DN 116:233518  
TI Effect of bromocriptine, a **prolactin antagonist**, on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and interleukin-2

AU Kumar, G. Sivan; Das, U. N.; Das, N. P.; Tan, B. K. H.  
CS Dep. Med., Nizam's Inst. Med. Sci., Hyderabad, 500 482, India  
SO Med. Sci. Res. (1992), 20(4), 141-2  
CODEN: MSCREJ; ISSN: 0269-8951

DT Journal  
LA English

L8 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2002 ACS  
AN 1992:504649 CAPLUS  
DN 117:104649  
TI Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary

AU Pisarek, H.; Stepien, H.; Pawlikowski, M.  
CS Inst. Endocrinol., Med. Acad., Lodz, 91-425, Pol.  
SO Endocr. Regul. (1992), 26(1), 17-22  
CODEN: EREGJ3

DT Journal  
LA English

L8 ANSWER 12 OF 35 MEDLINE  
AN 92170160  
DN 92170160 PubMed ID: 1792797  
TI Danazol in treatment of cystic mastopathy).

AU Danazol in der Behandlung der zystischen Mastopathie.  
AU Radivojvic, K  
CS II. Universitäts-Frauenklinik, Wien.  
CS WIENER KLINISCHE WOCHENSCHRIFT, (1991) 103 (23) 710-3.  
SO Journal code: XOP; 21620870R. ISSN: 0043-5325.  
Austria

CY (CLINICAL TRIAL)  
DT (CONTROLLED CLINICAL TRIAL)  
LA German  
FS (RANDOMIZED CONTROLLED TRIAL)  
EM 199204

ED Entered STN: 19920417  
 Last Updated on STN: 19970203  
 Entered Medline: 19920402

L8 ANSWER 13 OF 35 MEDLINE  
 AN 92005963  
 DN 92005963 Pubmed ID: 1914033  
 TI Treatment of breast proliferation disease with modified xiao yao san and  
 AU Zhang G L  
 SO Dept. of Surgery TCM, First Affiliated Hospital, Shanxi Medical College,  
 Talyuan.  
 CS CHUNG HSI I CHIEH HO TSA CHIH CHINESE JOURNAL OF MODERN DEVELOPMENTS IN  
 TRADITIONAL MEDICINE, (1991 Jul) 11 (7) 400-2, 388.  
 Journal code: CZU; 8207427. ISSN: 0254-9034.  
 CY China  
 DT Journal: Article; (JOURNAL ARTICLE)  
 LA Chinese  
 FS Priority Journals  
 EM 199111  
 ED Entered STN: 19920124  
 Last Updated on STN: 19920124  
 Entered Medline: 19911105

L8 ANSWER 14 OF 35 CANCERLIT  
 AN 92005963 CANCERLIT  
 DN 92005963  
 TI Treatment of breast proliferation disease with modified xiao yao san and  
 AU Zhang G L  
 CS Dept. of Surgery TCM, First Affiliated Hospital, Shanxi Medical College,  
 Talyuan.  
 SO CHUNG HSI I CHIEH HO TSA CHIH CHINESE JOURNAL OF MODERN DEVELOPMENTS IN  
 TRADITIONAL MEDICINE, (1991). Vol. 11, No. 7 400-2, pp. 388.  
 Journal code: CZU. ISSN: 0254-9034.  
 DT Journal: Article; (JOURNAL ARTICLE)  
 FS MEDL: 1  
 LA Chinese  
 OS MEDLINE 92005963  
 EM 199112

L8 ANSWER 15 OF 35 MEDLINE  
 AN 92069294 MEDLINE  
 DN 92069294 Pubmed ID: 1958840  
 TI Physiological significance of hormones and related substances in milk with  
 AU special reference to prolactin: an overview.  
 AU Nagasawa H  
 CS Experimental Animal Research Laboratory, Meiji University, Kanagawa,  
 Japan.  
 SO ENDOCRINE REGULATIONS, (1991 Jun) 25 (1-2) 90-7. Ref: 45  
 Journal code: A73; 9112018. ISSN: 1210-0668.  
 CY Czechoslovakia  
 DT Journal: Article; (JOURNAL ARTICLE)  
 LA General Review; (REVIEW)  
 FS (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199201  
 ED Entered STN: 19920124  
 Last Updated on STN: 19920124  
 Entered Medline: 19920107

L8 ANSWER 16 OF 35 MEDLINE  
 AN 90065446 MEDLINE  
 DUPLICATE 7

DN 90065446 Pubmed ID: 2585998  
 TI [Bromocriptine: a new therapy concept in the treatment of chronic  
 recurrent uveitis?].  
 AU Zierhut M; Pleyer U; Waectjen R; Thiel H J; Weide E G  
 CS Abteilung I, Universitäts-Augenklinik Tübingen.  
 SO KLINISCHE MONATSBLÄTTER FÜR AUGENHEILKUNDE, (1989 Oct) 195 (4) 221-5.  
 Journal code: KWA; 0014133. ISSN: 0023-2165.  
 CY GERMANY, WEST: Germany, Federal Republic of  
 DT Journal: Article; (JOURNAL ARTICLE)  
 LA German  
 FS Priority Journals  
 EM 198912  
 ED Entered STN: 19900328  
 Last Updated on STN: 19900328  
 Entered Medline: 19891227

L8 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1987:423564 CAPLUS  
 DN 107:23564  
 TI Preparation of (+)-isochanoclavine-I  
 IN Somei, Masanori  
 PA Kissei Pharmaceutical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 5 pp.  
 DT Patent  
 LA Japanese  
 FAN: CMT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62063569	A2	19870320	JP 1985-203890	19850913
JP 02034347	B4	19900802		

L8 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1986:219446 CAPLUS  
 DN 104:219446  
 TI Mechanisms of action inhibitors of prolactin secretion in GH3 pituitary  
 AU Wolfe, Susan E.; Brostrom, Margaret A.  
 CS Dep. Pharmacol., Univ. Med. Dent. New Jersey, Piscataway, NJ, 08854, USA  
 SO Mol. Pharmacol. (1986), 29(4), 420-6  
 CODEN: MOPMA3; ISSN: 0026-895X  
 DT Journal  
 LA English

L8 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1986:219445 CAPLUS  
 DN 104:219445  
 TI Mechanisms of action of inhibitors of prolactin secretion in GH3 pituitary  
 AU Wolfe, Susan E.; Brostrom, Charles O.; Brostrom, Margaret A.  
 CS Dep. Pharmacol., Univ. Med. Dent. New Jersey, Piscataway, NJ, 08854, USA  
 SO Mol. Pharmacol. (1986), 29(4), 411-15  
 CODEN: MOPMA3; ISSN: 0026-895X  
 DT Journal  
 LA English

L8 ANSWER 20 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 86013861 EMBASE  
 DN 1986013861  
 TI Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT  
 AU mouse mammary carcinoma.  
 AU Zaccheo T.

CS Experimental Oncology, Farmitalia Carlo Erba Research Institute, 20014  
 SO Nerviano, Milano, Italy  
 Cancer Letters, (1985) 28/2 (237-241).  
 CODEN: CALEDO

CY Ireland  
 DT Journal

FS 037 Drug Literature Index  
 003 Endocrinology  
 010 Obstetrics and Gynecology  
 016 Cancer  
 009 Surgery  
 030 Pharmacology  
 LA English

L8 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1985:72129 CAPLUS  
 DN 102:72129

TI Pharmacology of prolactin antagonists  
 AU Jean-Joseph, Patricia; Bouchard, Philippe; Schaison, Gerard  
 CS Serv. Endocrinol., Hop. Bicetre, Le Kremlin-Bicetre, 94270, Fr.  
 SO Vie Med. (1984), 65(23), 911-12, 914, 917-18, 920  
 CODEN: VIMEAL; ISSN: 0042-5591

DT Journal: General Review  
 LA French

L8 ANSWER 22 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 1985:48886 BIOSIS  
 DN BR28:48886

TI ACCIDENTAL BROMOCRIPTINE INGESTION IN CHILDHOOD.  
 AU VERMUND S H; GOLDSTEIN R G; ROMANO A A; ATWOOD S J  
 CS DIV. EPIDEMIOLOG., 600 W. 168TH ST., NEW YORK, N.Y. 10032.  
 SO J. Pediatr. (St. Louis), (1984) 105 (5), 838-840.  
 CODEN: JOPDAB; ISSN: 0022-3476.  
 FS BR: OLD  
 LA English

L8 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1982:437077 CAPLUS  
 DN 97:37077

TI A possible role of prolactin in adjuvant arthritis  
 AU Berczi, I.; Nagy, E.  
 CS Dep. Immunol., Univ. Manitoba, Winnipeg, MB, R3E 0W3, Can.  
 SO Arthritis Rheum. (1982), 25(5), 591-4  
 CODEN: ARHEAW; ISSN: 0004-3591

DT Journal  
 LA English

L8 ANSWER 24 OF 35 MEDLINE  
 AN 83006317 MEDLINE  
 DN 83006317 PubMed ID: 6889585

TI The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin.  
 AU Jeromin L  
 SO INTERNATIONAL UROLOGY AND NEPHROLOGY, (1982) 14 (1) 51-6.  
 Journal code: GUQ; 0262521. ISSN: 0301-1623.

CY Hungary  
 DT Journal: Article; (JOURNAL ARTICLE)

LA English  
 FS Priority Journals  
 EM 198212

ED Entered STN: 19900317  
 Last Updated on STN: 19900317  
 Entered Medline: 19821202

L8 ANSWER 25 OF 35 CANCERLIT  
 AN 81618709 CANCERLIT  
 DN 81618709

TI ROLE OF PROLACTIN IN THE DEVELOPMENT OF MAMMARY GLAND TUMORS INDUCED BY DIETHYLENZANTHRACENE.  
 AU Devot I I; Demina N A  
 CS Lab. Experimental Biology of Tumors, Oncologic Scientific Center, Acad. Medical Sciences USSR, Moscow, USSR.  
 SO Bull Exp Biol Med, (1981). Vol. 90, No. 9, pp. 1278-1280.  
 ISSN: 0007-4888

DT Journal: Article; (JOURNAL ARTICLE)

FS ICD8  
 LA English  
 EM 198107

L8 ANSWER 26 OF 35 MEDLINE  
 AN 82089205 MEDLINE  
 DN 82089205 PubMed ID: 7316110

TI Prolactin and contact sensitivity.  
 AU Nagy E; Berczi I  
 SO ALLERGY, (1981 Aug) 36 (6) 429-31.  
 Journal code: 39C; 7804028. ISSN: 0105-4538.

CY Denmark  
 DT Journal: Article; (JOURNAL ARTICLE)

LA English  
 FS Priority Journals  
 EM 198202

ED Entered STN: 19900316  
 Last Updated on STN: 19900316  
 Entered Medline: 19820212

L8 ANSWER 27 OF 35 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 1982:171345 BIOSIS  
 DN BA73:31329

TI THE IMPORTANCE OF PROLACTIN IN THE GESTATION OF THE ROE DEER CAPREOLUS-CAPREOLUS-CAPREOLUS.  
 AU VON FISCHER B  
 CS UNIV.-FRAUENKLIN. BERN, SCHANZENECKSTR. 1, CH-3012 BERN, SWITZ.  
 SO Z. SAEGETIERK, (1981) 46 (4), 259-264.  
 CODEN: ZSAE7; ISSN: 0044-3468.  
 FS BA: OLD  
 LA German

L8 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1980:52243 CAPLUS  
 DN 92:52243

TI How can maternal lactation be inhibited?  
 AU Baudet, J. H.; Pichereau, D.; Peter, J.; Brouquet, J.  
 CS Hop. Univ. Dupuytren, Limoges, 87000, Fr.  
 SO Gaz. Med. Fr. (1979), 86(33), 3795-6, 3798  
 CODEN: GAMF7; ISSN: 0016-5557

DT Journal: General Review  
 LA French

L8 ANSWER 29 OF 35 CANCERLIT  
 AN 80654353 CANCERLIT  
 DN 80654353

TI HYPERPROLACTINEMIA INDUCED BY ANTIEMETICS: COMPARISON OF FOUR DRUGS).  
 AU Segrestaa J M; Guertis J; Julien D; Tiar M  
 CS Unite de Recherche sur la Pathologie Iatrogene, Hopital Lariboisiere, 2, rue Ambroise Pare, 75010 Paris, France.  
 SO Therapie, (1979). Vol. 34, No. 4, pp. 437-443.  
 ISSN: 0040-5957.



DT Journal; Article; (JOURNAL ARTICLE)  
 FS ICDB  
 LA French  
 EM 198006

L8 ANSWER 30 OF 35 MEDLINE  
 AN 80116495 MEDLINE  
 DN 80116495 Pubmed ID: 528777  
 TI Influence of bromocriptine on plasma levels of prolactin and steroid hormones in the 20th week of pregnancy.  
 AU Lehmann W D; Musch K; Wolf A S  
 SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, (1979 JUL-SEP) 2 (3) 251-5.  
 Journal code: IAM; 7806594. ISSN: 0391-4997.

CY Italy  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198004  
 ED Entered STN: 19900315  
 Last Updated on STN: 19900315  
 Entered Medline: 19800417

L8 ANSWER 31 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 79018228 EMBASE  
 DN 1979018228  
 TI [Prolactin and ovarian function].  
 AU PROLATTINA E FUNZIONE OVARICA.  
 Rendina M.; Donadio C.; Martore G.B.  
 CS I Div. Ostet. Ginecol., Osp. San Camillo de Lellis, Roma, Italy  
 SO Patologia e Clinica Ostetrica e Ginecologica, (1978) 6/4 (196-207).  
 CODEN: PCOGBW

CY Italy  
 DT Journal  
 FS 037 Drug Literature Index  
 010 Obstetrics and Gynecology  
 003 Endocrinology  
 030 Pharmacology  
 LA Italian  
 SL English

L8 ANSWER 32 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 78356542 EMBASE  
 DN 1978356542  
 TI Hormonal control of breast cancer growth in women and rats.  
 AU Pearson O.H.; Manni A.  
 CS Dept. Med., Case West. Reserve Univ. Sch. Med., Cleveland, Ohio, United States  
 SO Current Topics in Experimental Endocrinology, (1978) VOL.3/- (75-92).  
 CODEN: CTEBAJ

CY United States  
 DT Journal  
 FS 037 Drug Literature Index  
 003 Endocrinology  
 010 Obstetrics and Gynecology  
 016 Cancer  
 LA English

L8 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2002 ACS  
 AN 1978:15598 CAPLUS  
 DN 88:15598  
 TI The treatment of various forms of ovarian insufficiency with prolactin-inhibiting substances  
 AU Schulz, K. D.  
 CS Univ.-Frauenklin. Koeln, Cologne, Ger.

SO Therapiewoche (1977), 27(1), 96-8, 101  
 CODEN: THEWA6  
 DT Journal; General Review  
 LA German

L8 ANSWER 34 OF 35 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 AN 76182512 EMBASE  
 DN 1976182512  
 TI Galactorrhea: past and present concepts.  
 AU Cooperstein M.S.  
 CS Dept. Obstet. Gynecol., John F. Kennedy Mem. Hosp., Stratford, N.J.  
 SO Journal of the American Osteopathic Association, (1975) 75/3 (334-339).  
 CODEN: JAOAAZ

DT Journal  
 FS 037 Drug Literature Index  
 010 Obstetrics and Gynecology  
 003 Endocrinology  
 009 Surgery  
 006 Internal Medicine  
 LA English

L8 ANSWER 35 OF 35 MEDLINE  
 AN 60035327 MEDLINE  
 DN 60035327  
 TI Inactivation of prolactin by human blood serum and plasmin (fibrinolysin).  
 AU HOPKINS T F; MEITES J; RAYNER A  
 SO Proc Soc Exp Biol Med, (1961 Jan) 106 140-1.  
 DT Journal  
 LA English  
 FS OLDMEDLINE  
 EM 196112  
 ED Entered STN: 19990716  
 Last Updated on STN: 19990716

=> his  
 HIS IS NOT A RECOGNIZED COMMAND  
 The previous command name entered was not recognized by the system.  
 For a list of commands available to you in the current file, enter  
 "HELP COMMANDS" at an arrow prompt (=>).

=> d his  
 (FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002)  
 FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOSIS, USPATFULL' ENTERED AT  
 10:34:58 ON 25 APR 2002  
 L1 246870 S FUSION PROTEIN? OR CHIMER?  
 L2 17094 S IL2 OR INTERLEUKIN 2 AND IL1  
 L3 27059 S IL1 AND INTERLEUKIN 12 OR IL12  
 L4 208008 S IL1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN  
 L5 10 S PROLACTIN AGONIST  
 L6 80 S PROLACTIN ANTAGONIST  
 L7 55 S L6 NOT PY=>2000  
 L8 35 DUP REM L7 (20 DUPLICATES REMOVED)

=> s 16 and 11  
 L9 4 L6 AND L1  
 => d 19 1-4 ibib  
 L9 ANSWER 1 OF 4 MEDLINE  
 ACCESSION NUMBER: 2001095543 MEDLINE

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NI, TD, TG  
 PRIORITY APPL. INFO.: US 2000-191457P P 20000323

L9 a ANSWER 4 OF 4 USPATFULL a  
 ACCESSION NUMBER: 2001:194148 USPATFULL  
 TITLE: PROLACTIN ANTAGONISTS AND USES

INVENTOR(S): WALKER, AMEME M., RIVERSIDE, CA, United States  
 { }

PATENT INFORMATION: US 2001:036662 A1 20011101  
 APPLICATION INFO.: US 1998-65330 A1 19980423 (9)  
 WO 1997-US1435 19970130

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: KNOBE MATTEUS OLSON & BEAR LLP, 620 NEWPORT CENTER  
 DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660

NUMBER OF CLAIMS: 13  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 2 Drawing Page(s)  
 LINE COUNT: 1083

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOSIS, USPATFILL' ENTERED AT 10:34:58 ON 25 APR 2002

L1 246870 S FUSION PROTEIN? OR CHIMER?  
L2 17094 S IL2 OR INTERLEUKIN 2 AND IL1  
L3 27059 S IL2 AND INTERLEUKIN 12 OR IL12  
L4 208008 S IL1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN  
L5 10 S PROLACTIN AGONIST  
L6 80 S PROLACTIN ANTAGONIST  
L7 55 S L6 NOT PY=>2000  
L8 35 DUP REM L7 (20 DUPLICATES REMOVED)  
L9 4 S L6 AND L1  
L10 1358 S IMMUNOMODULATOR? AND L1  
L11 1124 DUP REM L10 (234 DUPLICATES REMOVED)  
L12 509 S L11 NOT PY=>2000  
L13 100 S L12 AND INTERLEUKIN 2  
L14 8 S L12 AND INTERFERON GAMMA  
L15 70916 S L12 AND INTERFERON GAMMA OR GAMMA INTERFERON  
L16 76 S L12 AND GAMMA INTERFERON  
L17 71 S L12 AND INTERFERON GAMMA

=> d 117 1-71

L17 ANSWER 1 OF 71 MEDLINE  
AN 97405413 MEDLINE  
DN 97405413 PubMed ID: 9262056  
TI Molecular cloning and expression of a fungal immunomodulatory protein, FIP-five, from *Flammulina velutipes*.  
AU Ko J L, Lin S J, Hsu C I, Rao C L, Lin J Y  
CS Institute of Biochemistry, College of Medicine, National Taiwan University, Taipei, ROC.  
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, (1997 Jul) 96 (7) 517-24.  
CY TAINAN: Taiwan, Province of China  
DT Journal: Article: (JOURNML ARTICLE)  
LA English  
FS Priority Journals  
EM 199709  
ED Entered STN: 19970926  
Last Updated on STN: 19970916  
Entered Medline: 19970916

L17 ANSWER 2 OF 71 MEDLINE  
AN 92330820 MEDLINE  
DN 92330820 PubMed ID: 1628125  
TI The role of recombinant cytokines and other immunomodulators on engraftment following allogeneic bone marrow transplantation in mice.  
AU Biedler A, Weiss L, Slavin S  
CS Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.  
SO BONE MARROW TRANSPLANTATION, (1992 Jun) 9 (6) 421-6.  
CY ENGLAND: United Kingdom  
DT Journal: Article: (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199208  
ED Entered STN: 19920904  
Last Updated on STN: 19920904  
Entered Medline: 19920820

L17 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2002 ACS

AN 1999:592512 CAPLUS  
DN 132:92016  
TI Effect of different adjuvants and immunomodulators on the humoral immune response of rabbits and mice against HIV-1-derived multi-epitope polypeptides

AU Herrera, Antonieta M.; Vazquez, Dania; Navea, Leonor; Lobaina, Leonor; Quintana, Diogenes; Napoles, Annara; Garcia, Yanela; Duarte, Carlos A.  
CS Vaccine Division, AIDS Department, Center for Genetic Engineering and Biotechnology, Havana, 10600, Cuba  
SO Biocologia Aplicada (1999), 16(2), 103-108  
CODEN: BIAPEP; ISSN: 0864-4551  
PB Sociedad Iberoamericana de Biocologia Aplicada a la Salud  
DT Journal  
LA English  
RE.CNT 28  
ALL CITATIONS AVAILABLE IN THE RE FORMAT  
THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

L17 ANSWER 4 OF 71 CAPLUS COPYRIGHT 2002 ACS  
AN 1999:309088 CAPLUS  
DN 131:143197  
TI Construction of chimeric immunogens: Bioactive fragment of human IL-1-beta or poly(I:C) (PI) capable of eliciting immune responses to HIV peptides  
AU Gokuliah, K.; Khare, S.; Rao, D. N.  
CS Department of Biochemistry, All India Institute of Medical Sciences New Delhi, New Delhi, 110 029, India  
SO Indian Journal of Clinical Biochemistry (1998), 13(2), 111-118  
CODEN: IJCBEY; ISSN: 0970-1915  
PB Association of Clinical Biochemists of India  
DT Journal  
LA English  
RE.CNT 25  
THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2002 ACS  
AN 1995:996653 CAPLUS  
DN 124:53725  
TI Cellular immune response-specific antigens as vaccines for treatment of tumors and infections  
IN Longenecker, B. Michael; Ding, Lei; Reddish, Mark A.; Koganly, Raghupathi Rao  
PA Biomira, Inc., Can.  
SO PCT Int. Appl., 141 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1  
PATENT NO. KIND DATE APPLICATION NO. DATE

WO 9527505 A1 19951019 WO 1995-US4540 19950412  
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA  
RW: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG  
AU 9522470 A1 19951030 AU 1995-22470 19950412  
PRAI US 1994-229606 19940412  
WO 1995-US4540 19950412

L17 ANSWER 6 OF 71 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
AN 1999222808 EMBASE

TI Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects, indications.

AU Baert F.J.; Rutgeerts P.R.  
P.R. Rutgeerts, Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

CS Paul Rutgeerts@kuleuven.ac.be  
International Journal of Colorectal Disease, (1999) 14/1 (47-51).

SO Refs: 29  
ISSN: 0179-1958 CODEN: IUCDE6

CY Germany  
DT Journal, Article  
FS 005 General Pathology and Pathological Anatomy  
026 Immunology, Serology and Transplantation  
029 Clinical Biochemistry  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
048 Gastroenterology

LA English  
SL English

L17 ANSWER 7 OF 71 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1993:500167 BIOSIS  
DN PREV199396124174  
TI Fungal beta-glucans modulate macrophage release of tumor necrosis factor-alpha in response to bacterial lipopolysaccharide.  
AU Hoffman, Orleen A.; Olson, Eric J.; Limper, Andrew H. (1)  
CS (1) Thoracic Diseases, E-18B Mayo Clinic, Rochester, MN 55905 USA  
SO Immunology Letters, (1993) Vol. 37, No. 1, pp. 19-25.  
ISSN: 0165-2478.

DT Article  
LA English

L17 ANSWER 8 OF 71 USPTFULL  
AN 1999:163694 USPTFULL  
TI Substituted 4-amino-7H-pyrimidino [2,3,-d]-pyrimidines as PTK inhibitors  
IN Calderwood, David J.; Nottingham, United Kingdom  
Johnston, David N.; Nottingham, United Kingdom  
Raftery, Paul; Nottingham, United Kingdom  
Twigg, Helen L.; Nottingham, United Kingdom  
Munschaer, Rainer; Shrewsbury, MA, United States  
Arnold, Lee, Westborough, MA, United States  
BASF Aktiengesellschaft, Rheinland-Pfalz, Germany, Federal Republic of (non-U.S. corporation)  
PI US 6001839 19991214  
AI US 1998-42702 19980317 (9)  
PRAI US 1997-40836P 19970319 (60)  
DT Utility  
FS Granted  
LN.CNT 2239  
INCL INCLM: 514/258.000  
INCLS: 544/280.000  
NCL NCLM: 514/265.100  
NCLS: 544/280.000  
IC [6]  
ICM: C07D487-04  
ICS: A61K031-505  
EXF 544/280; 514/258

L17 ANSWER 9 OF 71 USPTFULL  
AN 1999:160214 USPTFULL  
TI Immunoadhesins and methods of production and use thereof  
AU Csaky, Karl G.; Kensington, MD, United States  
IN Anglade, Eddy, Silver Spring, MD, United States

PA Sullivan, Daniel M.; Galtersburg, MD, United States  
Laroche, William, Galtersburg, MD, United States  
The United States of America, as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 5998598 19991207 (8)  
AI US 1997-814567 19970310 (8)  
DT Utility  
FS Granted  
LN.CNT 2608  
INCL INCLM: 536/023.400  
INCLS: 435/320.100; 514/044.000; 536/023.100; 536/023.530; 536/023.720;  
NCL NCLM: 536/024.100  
NCLS: 435/320.100; 536/023.100; 536/023.530; 536/023.720; 536/024.100  
IC [6]  
ICM: A61K048-00  
ICS: C07H021-04; C12N015-62; C12N015-13  
EXF 435/320.1; 514/44; 536/23.4; 536/23.5; 536/23.53; 536/23.72; 536/24.1; 536/23.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 71 USPTFULL  
AN 1999:146760 USPTFULL  
TI Phosphorylated fusion proteins  
IN Pestka, Sidney, North Caldwell, NJ, United States  
PBL Biomedical Laboratories, New Brunswick, NJ, United States (U.S. corporation)  
PI US 5986061 19991116  
AI US 1995-482087 19950607 (8)  
R1I Continuation of Ser. No. US 1995-375112, filed on 19 Jan 1995 which is a continuation of Ser. No. US 1993-156875, filed on 23 Nov 1993, now abandoned which is a continuation of Ser. No. US 1988-264271, filed on 28 Oct 1988, now abandoned

DT Utility  
FS Granted  
LN.CNT 2596  
INCL INCLM: 530/352.000  
INCLS: 435/069.510; 435/071.200; 435/069.700; 435/471.000; 435/325.000;  
NCL NCLM: 435/252.300; 435/320.100; 536/023.400; 536/023.500; 536/023.520;  
NCLS: 424/001.410; 424/001.490  
IC [6]  
ICM: C07K014-56  
ICS: C07K014-565; C12N015-62  
EXF 530/351; 530/352; 435/69.51; 435/71.1; 435/71.2; 435/69.7; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471; 536/23.4; 536/23.5; 536/23.52; 935/11; 935/22; 935/27; 935/66; 935/72; 424/1.41; 424/1.49

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 71 USPTFULL  
AN 1999:117645 USPTFULL  
TI Products and processes for regulation of gene recombination  
IN Dreyfus, David H.; Denver, CO, United States  
Gelfand, Erwin W.; Englewood, CO, United States  
National Jewish Medical and Research Center, Denver, CO, United States (U.S. corporation)  
PI US 5958074 19990928  
AI US 1997-807332 19970228 (8)  
PRAI US 1996-12616P 19960301 (60)  
DT Utility  
FS Granted

LN.CNT 2196  
INCL INCLM: 530/300.000  
INCIS: 530/324.000  
NCL NCLM: 530/300.000  
NCLS: 530/324.000  
IC [6]  
ICM: C07K014-00  
EXF 530/300; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329; 530/330;  
530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 71 USPATFULT  
AN 1999:117243 USPATFULT  
TI Methods and compositions for regulating T cell subsets by modulating  
transcription factor activity  
IN Glimcher, Laurie H., West Newton, MA, United States  
PA Ho, I-Cheng, Newton, MA, United States  
PI Presidents and Fellows of Harvard College, Cambridge, MA, United States  
AI (U.S. corporation)  
DT US 5958671  
FS US 1996-636602  
LN.CNT 2803  
INCL INCLM: 435/004.000  
INCIS: 435/006.000; 435/029.000; 435/375.000; 435/455.000  
NCL NCLM: 435/004.000  
NCLS: 435/006.000; 435/029.000; 435/375.000; 435/455.000  
IC [6]  
ICM: C12N001-02  
EXF 435/4; 435/29; 435/6; 435/172.3; 435/375; 435/34-37; 435/455  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 71 USPATFULT  
AN 1999:113365 USPATFULT  
TI Tuberculosis vaccine  
IN Andersen, Peter, Bronshoj, Denmark  
Andersen, Peter, Bronshoj, Denmark  
Andersen, Peter, Bronshoj, Denmark  
Haslov, Kaare, Soborg, Denmark  
Sorensen, Anne Lund, Bronshoj, Denmark  
PA Statens Serum Institut, Copenhagen, Denmark (non-U.S. corporation)  
PI US 5955077  
AI US 1995-465640  
RLI US 1995-465640  
DT Continuation-in-part of Ser. No. US 1993-123182, filed on 20 Sep 1993,  
now abandoned And Ser. No. WO 1994-DK273, filed on 1 Jul 1994  
FS Utility  
LN.CNT 2205  
INCL INCLM: 424/184.100  
INCIS: 424/185.100; 424/190.100; 424/234.100; 424/248.100; 435/069.300;  
435/071.100; 435/325.000; 530/300.000; 530/327.000; 530/344.000;  
530/350.000; 530/412.000; 536/023.700  
NCL NCLM: 424/184.100  
NCLS: 424/185.100; 424/190.100; 424/234.100; 424/248.100; 435/069.300;  
435/071.100; 435/325.000; 530/300.000; 530/327.000; 530/344.000;  
530/350.000; 530/412.000; 536/023.700  
IC [6]  
ICM: A61K039-00  
EXF 435/350; 530/300; 530/327; 530/344; 530/412; 540/12; 424/184.1;  
424/185.1; 424/190.1; 424/234.1; 435/69.3; 435/71.1; 435/325;  
536/23.7  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 71 USPATFULT  
AN 1999:89000 USPATFULT  
TI Cyclic nucleotide phosphodiesterases  
IN Au-Yang, Janice, Berkeley, CA, United States  
Cocks, Benjamin G., Palo Alto, CA, United States  
Coleman, Roger, Mountain View, CA, United States  
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States  
PA Fisher, Douglas A., Gpton, CT, United States  
Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
corporation)  
PI US 5932423  
AI US 1997-974565  
RLI Continuation-in-part of Ser. No. US 1996-624663, filed on 25 Mar 1996,  
now patented, Pat. No. US 5798246  
DT Utility  
FS Granted  
LN.CNT 2750  
INCL INCLM: 435/006.000  
INCIS: 435/069.100; 435/320.100; 435/325.000; 435/348.000; 536/023.200;  
536/023.500  
NCL NCLM: 435/006.000  
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/348.000; 536/023.200;  
536/023.500  
IC [6]  
ICM: C12N001-02  
EXF 435/6; 435/69.1; 435/70.3; 435/71.1; 435/71.2; 435/252.3;  
435/320.1; 435/325; 435/348; 536/23.1; 536/23.2; 536/23.5; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 15 OF 71 USPATFULT  
AN 1999:81756 USPATFULT  
TI Expression vector systems and method of use  
IN Schwartz, Robert J., Houston, TX, United States  
Demayo, Franco J., Houston, TX, United States  
PA O'Malley, Bert W., Houston, TX, United States  
Baylor College of Medicine, Houston, TX, United States (U.S.  
corporation)  
PI US 5925564  
AI US 1995-472809  
RLI Continuation-in-part of Ser. No. US 1994-209846, filed on 9 Mar 1994,  
now patented, Pat. No. US 5756264 And a continuation-in-part of Ser. No.  
US 1991-789919, filed on 6 Nov 1991, now patented, Pat. No. US 5298422  
DT Utility  
FS Granted  
LN.CNT 2905  
INCL INCLM: 435/325.000  
INCIS: 435/320.100  
NCL NCLM: 435/325.000  
NCLS: 435/320.100  
IC [6]  
ICM: C12N005-16  
EXF 435/320.1; 435/172.3; 435/325  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 71 USPATFULT  
AN 1999:81543 USPATFULT  
TI Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and  
ligand antibodies as therapeutic agents for the treatment of  
immunological disease  
IN Browning, Jeffrey L., Brookline, MA, United States  
Benjamin, Christopher D., Beverly, MA, United States

PA Hochman, Paula S., Brookline, MA, United States  
 Bogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 PI US 5925331 19990720  
 AI US 1995-505606 19950721 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1968  
 INCL INCLM: 424/143.100  
 INCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/808.000;  
 530/395.000; 530/387.100; 530/388.220; 530/388.230; 530/388.730;  
 530/388.850; 530/389.200  
 NCL NCLM: 424/143.100  
 NCLS: 424/144.100; 424/145.100; 424/156.100; 514/002.000; 514/008.000;  
 530/387.100; 530/388.220; 530/388.230; 530/388.730; 530/388.850;  
 530/389.200; 530/395.000  
 IC [6]  
 ICM: A61K039-395  
 EXF ICS: A61K038-16; C07K016-00; C07K016-28  
 514/218; 530/395; 530/387.1; 530/388.22; 530/388.23; 530/388.73;  
 530/388.85; 530/389.2; 424/143.1; 424/144.1; 424/145.1; 424/156.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 17 OF 71 USPTFLL  
 AN 1999-78600 USPTFLL  
 TI Cyclic GMP phosphodiesterase  
 IN Fisher, Douglas A., Groton, CT, United States  
 Gooding, Douglas H., Redwood City, CA, United States  
 Streeter, David Gray, Boulder Creek, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
 corporation)  
 PI US 5922595 19990713  
 AI US 1997-987466 19971209 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2391  
 INCL INCLM: 435/320.100  
 INCLS: 435/069.100; 435/006.000; 536/023.100; 536/023.500; 530/350.000  
 NCL NCLM: 435/320.100  
 NCLS: 435/006.000; 435/069.100; 530/350.000; 536/023.100; 536/023.500  
 IC [6]  
 ICM: C12N015-00  
 EXF 530/350; 435/320.1; 435/69.1; 435/6; 536/23.1; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 18 OF 71 USPTFLL  
 AN 1999-72572 USPTFLL  
 TI DNA transcription unit vaccines that protect against avian influenza  
 IN viruses and methods of use thereof  
 Webster, Robert, Memphis, TN, United States  
 PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S.  
 corporation)  
 PI US 5916879 19990629  
 AI US 1996-747286 19961112 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1891  
 INCL INCLM: 514/044.000  
 INCLS: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;  
 424/816.000  
 NCL NCLM: 514/044.000  
 NCLS: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;  
 536/023.720  
 IC [6]  
 ICM: A61K048-00

EXF ICS: C12N015-87; C12N015-44  
 536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 19 OF 71 USPTFLL  
 AN 1999-39934 USPTFLL  
 TI Treatment for insulin dependent diabetes  
 IN Burly, Linda C., West Newton, MA, United States  
 PA Bogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 PI US 5888507 19990330  
 AI US 1995-447118 19950522 (8)  
 DT Continuation-in-part of Ser. No. US 1993-29330, filed on 9 Feb 1993, now  
 abandoned  
 FS Utility  
 LN.CNT 1914  
 INCL INCLM: 424/130.100  
 INCLS: 424/133.100; 424/145.100; 424/152.100; 424/158.100; 424/172.100;  
 514/002.000  
 NCL NCLM: 424/130.100  
 NCLS: 424/133.100; 424/145.100; 424/152.100; 424/158.100; 424/172.100;  
 514/002.000  
 IC [6]  
 ICM: A61K039-395  
 EXF ICS: A01N037-18  
 424/143.1; 424/130.1; 424/133.1; 424/145.1; 424/152.1; 424/158.1;  
 424/172.1; 530/350; 514/2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 20 OF 71 USPTFLL  
 AN 1999-33242 USPTFLL  
 TI Method to prevent transplant rejection  
 IN Levy, Julia G., Vancouver, Canada  
 Obochl, Modestus O. K., Vancouver, Canada  
 PA QLT Phototherapeutics, Inc., Vancouver, Canada (non-U.S. corporation)  
 PI US 5882328 19990316  
 AI US 1996-759318 19961202 (8)  
 DT Continuation-in-part of Ser. No. US 1995-371707, filed on 13 Jan 1995,  
 now abandoned  
 FS Utility  
 LN.CNT 1461  
 INCL INCLM: 604/020.000  
 INCLS: 604/049.000; 424/810.000; 128/898.000  
 NCL NCLM: 604/020.000  
 NCLS: 128/898.000; 424/810.000; 604/500.000  
 IC [6]  
 ICM: A61M001-30  
 EXF ICS: 161M031-00  
 604/19; 604/48; 604/49; 514/885; 530/388.7; 530/388.73;  
 530/388.75; 530/388.8; 530/388.85; 424/810; 424/140.1; 128/898  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 21 OF 71 USPTFLL  
 AN 1999-24311 USPTFLL  
 TI Vaccine for enhanced production of IgA antibodies  
 IN Mond, James J., Jerusalem, Israel  
 PA Snapper, Clifford M., Potomac, MD, United States  
 Henry M. Jackson Foundation for the Advancement of Military Medicine,  
 Rockville, MD, United States (U.S. corporation)  
 PI US 5874085 19990223  
 AI US 1995-400322 19950308 (8)  
 DT Continuation-in-part of Ser. No. US 1994-315492, filed on 30 Sep 1994,  
 now abandoned which is a continuation-in-part of Ser. No. US

1993-150510, filed on 10 Nov 1993

DT Utility  
FS Granted  
LN.CNT 999  
INCL INCLM: 424/195.110  
INCLM: 424/184.100; 424/193.100; 424/194.100; 424/278.100; 424/085.200;  
NCLM: 424/195.110  
NCLM: 424/085.400; 424/197.110  
NCLM: 424/195.110  
NCLM: 424/085.200; 424/085.400; 424/184.100; 424/193.100; 424/194.100;  
NCLM: 424/197.110; 424/278.100  
IC [6]  
ICM: A61K039-00  
ICS: A61K038-18; A61K038-19; A61K039-02  
424/184.1; 424/278.4; 424/193.1; 424/85.2; 514/2; 514/8; 514/885  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 71 USPTAFULL  
AN 1993-21711 USPTAFULL  
TI CXG Chemokines as regulators of angiogenesis  
IN Strieter, Robert M., Ann Arbor, MI, United States  
Polverini, Peter J., Ann Arbor, MI, United States  
Kunkel, Steven L., Ann Arbor, MI, United States  
PA The Regent of the University of Michigan, Ann Arbor, MI, United States  
PI (U.S. corporation)  
AI US 5871723 19900216  
DT US 1995-46819 19950606 (8)  
FS Utility  
LN.CNT 6055  
INCL INCLM: 424/085.100  
INCLM: 514/002.000; 514/008.000; 514/012.000  
NCLM: 424/085.100  
NCLM: 514/002.000; 514/008.000; 514/012.000  
IC [6]  
ICM: A61K038-19  
ICS: 424/85.1; 514/2; 514/8; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 71 USPTAFULL  
AN 1998-157496 USPTAFULL  
TI CD40 coding sequences  
IN Seed, Brian, Boston, MA, United States  
Allen, Janet, Glasgow, Scotland  
Aruffo, Alejandro, Edmonds, WA, United States  
Camerini, David, Charlottesville, VA, United States  
Lautner, Leander, Gladenbach, Germany, Federal Republic of  
Oquendo, Carmen, Gladenbach, Germany, Federal Republic of  
Simmons, David, Headington, United Kingdom  
Stamenkovic, Ivan, Winchester, MA, United States  
Stangelin, Siegfried, Epstein, Germany, Federal Republic of  
Amiot, Martine, Nantes, France  
PA The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)  
PI US 5849898 19981215  
AI US 1995-485447 19950607 (8)  
RLI Division of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-98809, filed on 23 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-379076, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160416, filed on 25 Feb 1988, now abandoned

DT Utility  
FS Granted

LN.CNT 3541  
INCL INCLM: 536/023.500  
INCLM: 435/069.100; 435/257.300; 435/320.100  
NCLM: 536/023.500  
NCLM: 435/069.100; 435/257.300; 435/320.100  
IC [6]  
ICM: C12N015-12  
ICS: 536/23.5; 435/69.1; 435/252.3; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 24 OF 71 USPTAFULL  
AN 1998-157145 USPTAFULL  
TI Method for making unclipped HIV envelope protein  
IN Bertram, Phillip W., Portola Valley, CA, United States  
Fendly, Brian M., Half Moon Bay, CA, United States  
Gregory, Timothy J., Hillsborough, CA, United States  
Worm, Florian M., Foster City, CA, United States  
PA Genetech, Inc., S. San Francisco, CA, United States (U.S. corporation)  
PI US 5849533 19981215  
AI US 1997-802361 19970219 (8)  
RLI Continuation of Ser. No. US 1994-226162, filed on 11 Apr 1994, now patented, Pat. No. US 5674984 which is a division of Ser. No. US 1993-101669, filed on 2 Aug 1993, now abandoned which is a continuation of Ser. No. US 1992-834735, filed on 13 Feb 1992, now abandoned which is a division of Ser. No. US 1990-504785, filed on 3 Apr 1990, now abandoned

DT Utility  
FS Granted  
LN.CNT 2639  
INCL INCLM: 435/069.300  
INCLM: 424/188.100; 424/208.100; 435/172.300; 530/412.000; 530/413.000  
NCLM: 435/069.300  
NCLM: 424/188.100; 424/208.100; 530/412.000; 530/413.000  
IC [6]  
ICM: C12P021-00  
ICS: C12P021-02  
424/148.1; 424/160.1; 424/188.1; 424/208.1; 435/69.3; 435/172.3; 435/325; 435/352; 435/358; 435/362; 435/320.1; 530/412; 530/413  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 25 OF 71 USPTAFULL  
AN 1998-154116 USPTAFULL  
TI Fungal Protease  
IN Buxton, Frank, Holderstedeijweg 32, 4132 Murtz, Switzerland  
Hinnen, Albert, Am Planetarium 32, 07743 Jena, Germany, Federal Republic of  
PA Visser, Jacob, Hinkeloorseweg 5, 6703 CK Wengeningen, Netherlands  
PI US 5846802 19981208  
AI US 1994-225488 19940408 (8)  
RLI Continuation-in-part of Ser. No. US 1993-47214, filed on 13 Apr 1993, now abandoned  
PRAI GB 1997-810281 19970415  
DT GB 1993-5097 19930312  
FS Utility  
LN.CNT 2639  
INCL INCLM: 435/225.000  
INCLM: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;  
NCLM: 435/014.000; 435/028.000; 435/068.000; 536/023.200  
NCLM: 435/225.000  
NCLM: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;  
NCLM: 536/023.200  
IC [6]  
ICM: C12N015-57

ICS: C12N015-80; C12N019-34; C12N009-12  
 EXF 435/225; 435/69.1; 435/172.3; 435/252.3; 435/254.3; 435/320.1;  
 536/252.3; 536/23.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 26 OF 71 USPTFULL  
 AN 1998:133867; USPTFULL  
 TI Preparation and use of viral vectors for mixed envelope protein  
 IN Immunogenic composition against human immunodeficiency viruses  
 PA Stobod, Karen, Memphis, TN, United States  
 PI St. Jude Children's Research Hospital, Memphis, TN, United States (U.S.  
 corporation)  
 AI US 5846546 19981208  
 RLI US 1997-788815 19970123 (8)  
 DT Continuation-in-part of Ser. No. US 1996-590288, filed on 23 Jan 1996,  
 Utility  
 FS Granted  
 LN.CNT 2393  
 INCL INCLM: 424/202.100  
 NCL INCLM: 424/191.100; 424/208.100; 514/044.000; 536/023.720  
 NCLM: 424/202.100  
 NCLM: 424/199.100; 424/208.100; 514/044.000; 536/023.720  
 IC [6]  
 ICM: A61K039-295  
 EXF ICS: A61K039-12; A61K039-21; A01N043-04  
 424/199.1; 424/202.1; 424/208.1; 514/44; 536/23.72  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 71 USPTFULL  
 AN 1998:150739 USPTFULL  
 TI Alphavirus vector constructs  
 IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States  
 PA Polo, John M., San Diego, CA, United States  
 PI Ibanez, Carlos E., San Diego, CA, United States  
 RLI Chang, Stephen M. W., San Diego, CA, United States  
 DT Jolly, Douglas J., Leucadia, CA, United States  
 FS Driver, David A., San Diego, CA, United States  
 LN.CNT Belli, Barbara A., San Diego, CA, United States  
 INCL Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 NCLM: 19981201  
 NCLM: 19961030 (8)  
 NCLM: 1996-739167  
 NCLM: 1996-404796, filed on 20 Mar 1995 which is a  
 Continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1994-348472, filed on 30 Nov 1994, now abandoned which is a  
 continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1993-122791, filed on 15 Sep 1993, now abandoned  
 Utility  
 FS Granted  
 LN.CNT 10318  
 INCL INCLM: 435/069.300  
 NCLM: 435/320.100; 435/325.000; 435/235.100  
 NCLM: 435/069.300  
 NCLM: 435/235.100; 435/320.100; 435/325.000  
 IC [6]  
 ICM: C12P021-02  
 EXF ICS: C12N015-63; C12N005-10  
 435/320.1; 435/325; 435/69.3; 435/235.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 71 USPTFULL

AN 1998:134881 USPTFULL  
 TI Cloning vector, polylinker and methods  
 IN Seed, Brian, Boston, MA, United States  
 PA Aruffo, Alejandro, Edmonds, WA, United States  
 PI The General Hospital Corporation, Charlestown, MA, United States (U.S.  
 corporation)  
 AI US 5830731 19981103  
 RLI US 1997-861205 19970521 (8)  
 DT Continuation of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a  
 continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990,  
 now abandoned which is a continuation of Ser. No. US 1989-399076, filed  
 on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser.  
 No. US 1988-160416, filed on 25 Feb 1988, now abandoned  
 Utility  
 FS Granted  
 LN.CNT 3587  
 INCL INCLM: 435/172.300  
 NCLM: 435/252.300; 435/320.100; 536/024.200  
 NCLM: 435/091.410  
 NCLM: 435/252.300; 435/320.100; 536/024.200  
 IC [6]  
 ICM: C12N015-66  
 EXF 435/252.7; 435/320.1; 435/172.3; 536/24.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 71 USPTFULL  
 AN 1998:134627 USPTFULL  
 TI Yeast-based delivery vehicles  
 IN Duke, Richard C., Denver, CO, United States  
 PA Franzusoff, Alex, Boulder, CO, United States  
 PI Bellgrau, Donald, Denver, CO, United States  
 RLI University Technology Corporation, Boulder, CO, United States (U.S.  
 corporation)  
 AI US 5830463 19981103  
 RLI US 1994-340185 19941115 (8)  
 DT Continuation-in-part of Ser. No. US 1993-88322, filed on 7 Jul 1993, now  
 patented, Pat. No. US 5413914  
 Utility  
 FS Granted  
 LN.CNT 1929  
 INCL INCLM: 424/093.510  
 NCLM: 424/093.500; 424/093.200; 435/320.100; 435/375.000; 435/172.300;  
 435/069.100  
 NCLM: 424/093.510  
 NCLM: 424/093.200; 424/093.500; 435/069.100; 435/320.100; 435/375.000  
 IC [6]  
 ICM: C12N015-00  
 EXF ICS: C12N015-09; A61K048-00  
 435/320.1; 435/240.2; 435/6; 435/7.1; 435/172.3; 435/7.2; 435/7.31;  
 514/44; 935/62; 935/52; 935/56; 935/57; 935/34; 935/32;  
 424/93.1; 424/93.2; 424/93.21; 424/93.51; 424/93.5; 536/23.74  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 71 USPTFULL  
 AN 1998:119004 USPTFULL  
 TI Eukaryotic layered vector initiation systems  
 IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Santa Fe, CA, United  
 States 92067  
 PA Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States  
 PI 92109  
 RLI Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024  
 Driver, David A., 5142 Biltmore St., San Diego, CA, United States 92117  
 US 5814482 19980929  
 US 1996-739158 19961030 (8)



RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned

DT Utility

FS Granted

LN CNT 10431

INCL INCLM: 435/069.300 536/023.100; 536/024.100

NCL INCLM: 435/320.100; 536/023.100; 536/024.100

IC NCLM: 435/069.300

NCLM: 435/320.100; 536/023.100; 536/024.100

ICM: C12P021-00

ICS: C12N015-86; C07H021-04

EXF 435/69.3; 435/320.1; 536/23.1; 536/24.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 31 OF 71 USPTAFULL

AN 1998:11645 USPTAFULL

TI Compositions for conferring immunogenicity to a substance and uses thereof

IN Stanton, G. John, Texas City, TX, United States

Hughes, Jr., Thomas K., Galveston, TX, United States

Smith, Eric M., Galveston, TX, United States

Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

PA US 5807552 19980915

PI US 1995-511662 19950804 (8)

AI Utility

FS Granted

LN CNT 2678

INCL INCLM: 424/188.100 530/324.000; 530/333.000; 530/826.000; 514/002.000; 514/012.000; 514/934.000; 535/005.000; 535/974.000

NCLM: 424/188.100; 424/186.100; 514/002.000; 514/012.000; 514/934.000

NCLM: 424/184.100; 424/186.100; 514/002.000; 514/012.000; 514/934.000

NCLM: 530/324.000; 530/333.000; 530/826.000

IC (6)

ICM: A61K039-21

EXF 530/324-331; 530/333; 530/334; 530/826; 435/5; 435/974; 424/184.1; 424/186.1; 424/188.1; 514/2; 514/12-19; 514/934

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 32 OF 71 USPTAFULL

AN 1998:108036 USPTAFULL

TI Recombinant canine herpesviruses

IN Haanes, Elizabeth J., Berchoud, CO, United States

Frank, Rexann S., Wellington, CO, United States

Heeka Corporation, Ft. Collins, CO, United States (U.S. corporation)

PA US 5804197 19980908

PI US 1996-680726 19960712 (8)

RLI Continuation-in-part of Ser. No. US 1996-602010, filed on 15 Feb 1996

DT Utility

FS Granted

LN CNT 5536

INCL INCLM: 424/229.100 435/235.100; 435/320.100

NCLM: 424/199.100; 435/235.100; 435/320.100

NCLM: 424/229.100

NCLM: 424/199.100; 435/235.100; 435/320.100

IC (6)

ICM: A61K039-245

ICS: A61K039-00; C12N007-01; C12N015-00

EXF 424/229.1; 424/199.1; 435/235.1; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 33 OF 71 USPTAFULL

AN 1998:101537 USPTAFULL

TI Cyclic nucleotide phosphodiesterase

IN Au-Young, Janice, Berkeley, CA, United States

Cocks, Benjamin Graeme, Palo Alto, CA, United States

Coleman, Roger, Mountain View, CA, United States

Selhammer, Jeffrey J., Los Altos Hills, CA, United States

Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

PA US 5798246 19980825

PI US 1996-624663 19960325 (8)

AI Utility

FS Granted

LN CNT 1820

INCL INCLM: 435/196.000 435/320.100; 435/325.000; 536/023.200; 536/023.500

NCLM: 435/172.300; 435/320.100; 435/325.000; 536/023.200; 536/023.500

NCLM: 435/196.000

NCLM: 435/320.100; 435/325.000; 536/023.200; 536/023.500

IC (6)

ICM: C12N009-18

EXF 435/172.300; 435/320.100; 435/325.000; 536/023.200; 536/023.500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 34 OF 71 USPTAFULL

AN 1998:98981 USPTAFULL

TI Lymphotoxin-beta and lymphotoxin-beta complexes

IN Browning, Jeffrey, Brookline, MA, United States

Ware, Carl F., Riverside, CA, United States

Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

University of California, Oakland, CA, United States (U.S. corporation)

PA US 5795964 19980818

PI US 1995-467070 19950606 (8)

AI US 1994-222614, filed on 1 Apr 1994, now abandoned

RLI Division of Ser. No. US 1994-222614, filed on 1 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1990-544862, filed on 27 Jun 1990, now abandoned

DT Utility

FS Granted

LN CNT 2597

INCL INCLM: 530/351.000 530/350.000; 514/012.000; 536/023.400; 536/023.500

NCLM: 530/351.000

NCLM: 530/324.000; 530/350.000; 536/023.400; 536/023.500

IC (6)

ICM: C07K014-46

EXF 530/324; 530/350; 530/351; 514/12; 536/23.4; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 35 OF 71 USPTAFULL

AN 1998:98884 USPTAFULL

TI Analogs for specific oligosaccharide-protein interactions and uses therefor

IN Witt, Daniel P., Hamilton, MA, United States

Herlitz, Jr., Walter C., Beverly, MA, United States

Repligen Corporation, Needham, MA, United States (U.S. corporation)

PA US 5795860 19980818

PI US 1994-202989 19940228 (8)

RLI Continuation-in-part of Ser. No. US 1993-24558, filed on 1 Mar 1993, now abandoned

DT Utility  
FS Granted  
LN.CNT 2449  
INCL INCLM: 514/012.000; 514/054.000; 514/062.000; 530/350.000; 530/359.000;  
INCLM: 536/055.100; 536/055.200  
NCLM: 514/012.000  
NCLM: 514/002.000; 514/054.000; 514/062.000; 530/350.000; 530/359.000;  
NCLM: 514/002.000; 536/055.200  
IC [6]  
ICM: A01N037-18  
ICS: A61K031-70  
514/54; 514/56; 514/2; 514/12; 514/62; 536/55.1; 530/55.2; 530/350;  
530/359  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 36 OF 71 USPTFUL  
AN 1998:91872 USPTFUL  
TI Alphavirus structural protein expression cassettes  
IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States  
Polo, John M., San Diego, CA, United States  
Ibanez, Carlos E., San Diego, CA, United States  
Chang, Stephen M. W., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
Driver, David A., San Diego, CA, United States  
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 5789245 19961030 (8)  
US 1996-741881  
Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a  
continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-348472, filed on 30 Nov 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1994-188450, filed on 18 Feb 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1993-122791, filed on 15 Sep 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 10270  
INCL INCLM: 435/320.100  
INCLM: 435/691.000; 435/325.000; 536/023.720  
NCLM: 435/320.100  
NCLM: 435/069.100; 435/325.000; 536/023.720  
IC [6]  
ICM: C12N015-63  
ICS: C12N015-40; C12N005-10; C12P021-02  
435/320.1; 435/69.1; 435/325.536/23.72  
EXF 435/320.1; 435/69.1; 435/325.536/23.72  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 37 OF 71 USPTFUL  
AN 1998:68822 USPTFUL  
TI Cysteine-pegylated proteins  
IN Braxton, Scott M., San Mateo, CA, United States  
PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
corporation)  
PI US 5766897 19980616  
US 1995-427100 19950421 (8)  
Continuation-in-part of Ser. No. US 1993-144758, filed on 29 Oct 1993,  
now abandoned which is a continuation-in-part of Ser. No. US  
1992-924294, filed on 3 Aug 1992, now patented. Pat. No. US 5457090  
which is a continuation of Ser. No. US 1990-542484, filed on 21 Jun  
1990, now patented, Pat. No. US 5187089, issued on 16 Feb 1993  
DT Utility  
FS Granted  
LN.CNT 2765

INCL INCLM: 435/172.100  
INCLM: 435/188.000; 435/212.000; 435/219.000  
NCLM: 435/463.000  
NCLM: 435/188.000; 435/212.000; 435/219.000  
IC [6]  
ICM: C12N015-00  
ICS: C12N009-96; C12N009-48; C12N009-50  
514/12; 530/350; 435/69.2; 435/188; 435/172.1; 435/212; 435/219  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 38 OF 71 USPTFUL  
AN 1998:57762 USPTFUL  
TI Aspergillus niger vacuolar aspartyl protease  
IN Buxton, Frank, Mulfenz, Switzerland  
Jara, Gabor, Oberwil, Switzerland  
Vlasier, Jacob, Wageningen, Netherlands  
Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
PI US 5756338 19980526  
US 1996-731045 19961008 (8)  
Division of Ser. No. US 1994-328314, filed on 24 Oct 1994, now patented,  
Pat. No. US 5674728, issued on 7 Oct 1997  
PRAI GB 1993-810764 19931103  
DT Utility  
FS Granted  
LN.CNT 1957  
INCL INCLM: 435/219.000  
INCLM: 435/254.300; 536/023.200  
NCLM: 435/219.000  
NCLM: 435/254.300; 536/023.200  
IC [6]  
ICM: C12N009-62  
ICS: C12N015-57; C12N015-63; C12N015-80  
435/219; 435/254.3; 435/2; 536/23.2  
EXF 435/219; 435/254.3; 435/2; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 39 OF 71 USPTFUL  
AN 1998:57690 USPTFUL  
TI Expression vector systems and method of use  
IN Schwartz, Robert J., Houston, TX, United States  
Demayo, Franco J., Houston, TX, United States  
O'Walley, Bert W., Houston, TX, United States  
Baylor College of Medicine, Houston, TX, United States (U.S.  
corporation)  
PI US 5756264 19980526  
US 1994-209846 19940309 (8)  
Continuation-in-part of Ser. No. US 1991-789919, filed on 6 Nov 1991,  
now patented, Pat. No. US 5298422  
DT Utility  
FS Granted  
LN.CNT 2798  
INCL INCLM: 435/320.100  
INCLM: 435/172.300; 435/252.300; 536/024.100  
NCLM: 424/093.200  
NCLM: 424/093.200  
NCLM: 435/349.000; 435/455.000; 435/465.000; 514/044.000; 536/024.100  
IC [6]  
ICM: C12N005-10  
ICS: C12N015-63  
435/69.1; 435/172.3; 476/242.3; 436/32.1; 536/24.1  
EXF 435/69.1; 435/172.3; 476/242.3; 436/32.1; 536/24.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 40 OF 71 USPTFUL  
AN 1998:54490 USPTFUL  
TI Recombinant canine herpesviruses

IN Haanes, Elizabeth J., Boulder, CO, United States  
 PA Frank, Rexam S., Wellington, CO, United States  
 PI Hesa Corporation, Ft. Collins, CO, United States (U.S. corporation)  
 AI US 5752323 19980519  
 DT US 1996-602010 19960215 (8)  
 FS Utility  
 IN INCL INCLM: 424/229.100 435/235.100; 530/388.300; 530/395.000  
 INCLM: 424/147.100; 435/235.100; 530/388.300; 530/395.000  
 NCLM: 424/229.100  
 NCLM: 424/229.100  
 NCLM: 424/147.100; 435/235.100; 530/388.300; 530/395.000  
 IC [6]  
 ICM: A61K039-245  
 ICS: C12N007-01; C07K001-00; C12P021-02  
 EXF 424/229.1; 424/147.1; 435/235.1; 530/388.3; 530/395  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 41 OF 71 USPTFLL  
 AN 1998:42068 USPTFLL  
 TI Preparation and use of viral vectors for mixed envelope protein vaccines  
 IN against human immunodeficiency viruses  
 Owens, Randall J., Millington, TN, United States  
 PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)  
 PI US 5741492 19980421  
 AI US 1996-590288 19960123 (8)  
 DT Utility  
 FS Granted  
 IN INCL INCLM: 424/208.100  
 INCLM: 424/160.100; 424/199.100; 435/320.100; 514/044.000; 536/023.200  
 NCLM: 424/208.100  
 NCLM: 424/160.100; 424/199.100; 435/320.100; 514/044.000; 536/023.200  
 IC [6]  
 ICM: A61K045-00  
 ICS: A61K039-42; A61K038-00; C12N015-00  
 EXF 424/160.1; 424/199.1; 424/208.1; 435/320.1; 514/44; 536/23.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 42 OF 71 USPTFLL  
 AN 1998:36732 USPTFLL  
 TI Polynucleotide tuberculosis vaccine  
 IN Content, Jean, Rhode-Saint-Genese, Belgium  
 Huygen, Kris, Brussels, Belgium  
 PA Liu, Margaret A., Rosemont, PA, United States  
 Montgomery, Donna, Chalfont, PA, United States  
 Umer, Jeffrey, Chalfont, PA, United States  
 Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 N. V. Innogenetics S.A., Ghent, Belgium (non-U.S. corporation)  
 PI US 5736524 19980407  
 AI US 1994-338992 19941114 (8)  
 DT Utility  
 FS Granted  
 IN INCL INCLM: 514/044.000  
 INCLM: 435/066.000; 435/069.100; 435/172.300; 435/375.000; 435/320.100;  
 INCLM: 935/062.000; 935/056.000; 935/034.000; 935/065.000  
 NCLM: 514/044.000  
 NCLM: 435/066.000; 435/069.100; 435/320.100; 435/375.000  
 IC [6]  
 ICM: A61K048-00  
 ICS: C07H021-00; C12N015-79; C12N015-63

EXF 435/320.1; 435/69.1; 435/172.3; 435/243; 435/252.1; 514/44;  
 935/62; 935/55; 935/66; 935/70; 935/71; 935/73; 935/74; 935/72  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 43 OF 71 USPTFLL  
 AN 1998:27762 USPTFLL  
 TI Methods and compositions incorporating IP-10  
 IN Sarris, Andreas H., Houston, TX, United States  
 Broxmeyer, Hal B., Indianapolis, IN, United States  
 Ravetch, Jeff V., New York, NY, United States  
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
 Indiana University Foundation, Bloomington, IN, United States (U.S. corporation)  
 Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)  
 PI US 5728377 19980317  
 AI US 1993-94651 19930720 (8)  
 DT Utility  
 FS Granted  
 IN INCL INCLM: 424/085.100  
 INCLM: 435/069.500; 530/351.000  
 NCLM: 424/085.100  
 NCLM: 435/069.500; 530/351.000  
 IC [6]  
 ICM: A61K045-05  
 EXF 424/85.1; 435/69.5; 530/351.000; 935/13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 44 OF 71 USPTFLL  
 AN 97:117676 USPTFLL  
 TI Polyspecific immunconjugates and antibody composites for targeting the  
 IN multidrug resistant phenotype  
 Goldenberg, David M., Menham, NJ, United States  
 PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)  
 PI US 5698178 19971216  
 AI US 1996-629387 19960408 (8)  
 DT Division of Ser. No. US 1994-286430, filed on 5 Aug 1994  
 RLI Utility  
 FS Granted  
 IN INCL INCLM: 424/001.490  
 INCLM: 424/009.341; 424/009.600; 424/001.530  
 NCLM: 424/001.490  
 NCLM: 424/001.530; 424/009.341; 424/009.600  
 IC [6]  
 ICM: A61K049-00  
 EXF 424/9.341; 424/1.49; 424/9.6; 424/1.53  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 45 OF 71 USPTFLL  
 AN 97:104602 USPTFLL  
 TI Polyspecific immunconjugates and antibody composites for targeting the  
 IN multidrug resistant phenotype  
 Goldenberg, David M., Menham, NJ, United States  
 PA Immunomedics, Inc., Morris Plains, NJ, United States (U.S. corporation)  
 PI US 5686578 19971111  
 AI US 1994-286430 19940805 (8)  
 DT Utility  
 FS Granted  
 IN INCL INCLM: 530/387.300  
 INCLM: 530/391.100; 530/391.900; 530/389.700; 530/389.500; 530/388.800;

NCL INCLM: 530/388.850; 530/389.100; 530/388.200; 530/388.400  
 NCLM: 530/387.300  
 NCLM: 530/388.200; 530/388.400; 530/388.800; 530/388.850; 530/389.100;  
 530/389.500; 530/389.700; 530/391.100; 530/391.900  
 IC [61]  
 ICM: C07K016-00  
 ICS: C07K016-18; C07K016-28; C07K016-12  
 530/387.3; 530/391.1-391.9; 530/389.7; 530/389.5; 530/388.8; 530/388.85;  
 530/389.1; 530/388.2; 530/388.4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 46 OF 71 USPTAFULL  
 AN 97:91639 USPTAFULL  
 TI Method for isolation of unclipped HIV envelope protein  
 IN Bernan, Phillip W., Potola Valley, CA, United States  
 Gregory, Timothy J., Hillsborough, CA, United States  
 Warm, Florian M., Foster City, CA, United States  
 Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
 PI US 5674984 19971007  
 AI US 1994-226162 19940411 (8)  
 RLI Division of Ser. No. US 1993-101669, filed on 2 Aug 1993, now abandoned  
 which is a continuation of Ser. No. US 1992-834735, filed on 13 Feb  
 1992, now abandoned which is a division of Ser. No. US 1990-504785,  
 filed on 3 Apr 1990, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2652  
 INCL INCLM: 530/413.000  
 INCLM: 530/388.350; 530/412.000  
 NCLM: 530/413.000  
 NCLM: 530/388.350; 530/412.000  
 IC [6]  
 ICM: C07K001-22  
 424/148.1; 424/160.1; 424/188.1; 424/208.1; 530/388.35; 530/412; 530/413  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 47 OF 71 USPTAFULL  
 AN 97:91390 USPTAFULL  
 TI Aspergillus niger vacuolar aspartyl protease  
 IN Buxton, Frank, Miltenz, Switzerland  
 Jara, Gabor, Oberwill, Switzerland  
 Vasser, Jacob, Wageningen, Netherlands  
 Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
 PI US 5674728 19971007  
 AI US 1994-328314 19941024 (8)  
 PRAI EP 1993-810764 19931103  
 DT Utility  
 FS Granted  
 LN.CNT 2018  
 INCL INCLM: 435/225.000  
 INCLM: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/172.300;  
 435/320.100; 536/023.200  
 NCLM: 435/225.000  
 NCLM: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/320.100;  
 435/477.000; 435/488.000; 536/023.200  
 IC [61]  
 ICM: C12N015-58  
 ICS: C12N015-80; C12N015-90; C12N009-62  
 435/219; 435/223; 435/225; 435/252.3; 435/254.11; 435/254.3; 435/172.3;  
 435/320.1; 435/69.1; 536/23.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 48 OF 71 USPTAFULL  
 AN 97:86585 USPTAFULL  
 TI Method to enhance permeability of the blood/brain blood/nerve barriers to  
 therapeutic agents  
 IN Poduslo, Joseph F., 5719 St. Mary's Dr. NW, Rochester, MN, United States  
 55901  
 Curran, Geoffrey L., 629 23rd St. NE, Rochester, MN, United States  
 55906  
 PA Poduslo, Joseph F., Rochester, MN, United States (U.S. individual)  
 Curran, Geoffrey L., Rochester, MN, United States (U.S. individual)  
 PI US 5670477 19970923  
 AI US 1995-425376 19950420 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1978  
 INCL INCLM: 514/002.000  
 NCLM: 514/002.000  
 IC [6]  
 ICM: A61K023-02  
 514/2  
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 49 OF 71 USPTAFULL  
 AN 97:86267 USPTAFULL  
 TI Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical  
 IN Brown, Jeffrey, Brookline, MA, United States  
 Ware, Carl F., Riverside, CA, United States  
 Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 The University of California, Oakland, CA, United States (U.S. corporation)  
 PI US 5670149 19970923  
 AI US 1995-476489 19950606 (8)  
 RLI Continuation of Ser. No. US 1994-222614, filed on 1 Apr 1994, now  
 abandoned which is a continuation-in-part of Ser. No. US 1990-544862,  
 filed on 27 Jun 1990, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2504  
 INCL INCLM: 424/130.100  
 INCLM: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;  
 424/158.100; 435/069.500; 530/388.220; 530/388.240  
 NCLM: 424/130.100  
 NCLM: 424/133.100; 424/139.100; 424/141.100; 424/142.100; 424/145.100;  
 424/158.100; 435/069.500; 530/388.220; 530/388.240  
 IC [61]  
 ICM: A61K039-395  
 435/69.5; 435/172.1; 435/320.1; 530/388.22; 530/388.24; 424/130.1;  
 424/133.1; 424/139.1; 424/141.1; 424/142.1; 424/145.1; 424/158.1  
 EXF CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L17 ANSWER 50 OF 71 USPTAFULL  
 AN 97:75989 USPTAFULL  
 TI Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical  
 IN Brown, Jeffrey, Brookline, MA, United States  
 Ware, Carl F., Riverside, CA, United States  
 Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 The University of California, Oakland, CA, United States (U.S. corporation)  
 PI US 5661004 19970826  
 AI US 1995-484272 19950607 (8)  
 RLI Continuation of Ser. No. US 1994-222614, filed on 1 Apr 1994, now  
 abandoned which is a continuation of Ser. No. US 1992-990304, filed on 4  
 Dec 1992, now abandoned which is a continuation of Ser. No. US

1990-544862, filed on 27 Jun 1990, now abandoned

DT Utility

FS Granted

LN.CNT 2578

INCL INCLM: 435/069.100

NCL INCLM: 435/240.200; 536/023.500

NCLM: 435/069.100 NCLS: 435/325.000; 435/358.000; 435/366.000; 435/372.300; 536/023.500

IC ICM: C12N015-00

ICS: C12N015-11; C12N015-85

EXF 435/69.5; 435/69.1; 435/240.2; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 51 OF 71 USPTFUL

AN 97:47501 USPTFUL

TI Peptides that bind IL-2 receptors

IN Barrett, Ronald W., Sunnyvale, CA, United States

Chernov-Rogan, Tanja, Belmont, CA, United States

Davis, Ann M., Mountain View, CA, United States

Allymax Technologies, N.V., Curacao, Netherlands Antilles (non-U.S. corporation)

PI US 5635597 19970603

AI US 1994-250789 19940527 (8)

DT Utility

FS Granted

LN.CNT 2025

INCL INCLM: 530/327.000

NCL INCLM: 530/300.000; 530/350.000; 530/351.000

NCLM: 530/327.000

NCLS: 530/300.000; 530/350.000; 530/351.000

IC ICM: C07K007-08

EXF 530/300; 530/327; 530/350; 530/351

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 52 OF 71 USPTFUL

AN 97:47265 USPTFUL

TI Anti-oncoimmunin-M antibodies and uses thereof

IN Packard, Beverly, Rockville, MD, United States

Komoriva, Akira, Rockville, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 5635356 19970603

AI US 1994-218023 19940322 (8)

RI Continuation-in-part of Ser. No. US 1991-764695, filed on 23 Sep 1991, now patented, Pat. No. US 5364619 which is a continuation-in-part of

Ser. No. US 1991-707136, filed on 31 May 1991, now abandoned

DT Utility

FS Granted

LN.CNT 2403

INCL INCLM: 435/007.100

NCL INCLM: 530/387.700; 530/388.230; 530/387.300; 530/350.000; 530/351.000

NCLM: 435/007.100

NCLS: 530/350.000; 530/351.000; 530/387.300; 530/387.700; 530/388.230

IC ICM: C07K016-24

ICS: C07K014-52; C12P021-08; G01N033-53

EXF 530/388.1; 530/388.2; 530/387.7; 530/388.23; 530/387.3; 530/350;

530/351; 435/7.1; 435/7.21; 435/975

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 53 OF 71 USPTFUL

AN 97:29374 USPTFUL

=> d his

(FILE 'HOME' ENTERED AT 10:34:15 ON 25 APR 2002)

FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOSIS, USPATFULL' ENTERED AT 10:34:58 ON 25 APR 2002

L1 246870 S FUSION PROTEIN? OR CHIMER?  
L2 17094 S IL2 OR INTERLEUKIN 2 AND IL1  
L3 27059 S L1 AND INTERFERON GAMMA OR IL12  
L4 208008 S L1 AND INTERFERON GAMMA OR GAMMA INTERFERON OR IFN  
L5 10 S PROLACTIN AGONIST  
L6 80 S PROLACTIN ANTAGONIST  
L7 55 S L6 NOT PY=>2000  
L8 35 DUP REM L7 (20 DUPLICATES REMOVED)  
L9 4 S L6 AND L1  
L10 1358 S IMMUNOMODULATOR? AND L1  
L11 1124 DUP REM L10 (234 DUPLICATES REMOVED)  
L12 509 S L11 NOT PY=>2000  
L13 100 S L12 AND INTERLEUKIN 2  
L14 8 S L12 AND INTERLEUKIN 12  
L15 70916 S L12 AND INTERFERON GAMMA OR GAMMA INTERFERON  
L16 76 S L12 AND GAMMA INTERFERON  
L17 71 S L12 AND INTERFERON GAMMA

=> d 116 1-76

L16 ANSWER 1 OF 76 MEDLINE  
AN 97184551 MEDLINE  
DN 97184551 Pubmed ID: 9032353  
TI The hepatitis B virus core and e antigens elicit different Th cell  
subsets: antigen structure can affect Th cell phenotype.  
AU Milich D R; Schodel F; Hughes J L; Jones J E; Peterson D L  
CS Department of Molecular Biology, The Scripps Research Institute, La Jolla,  
California 92037, USA.  
NC A120720 (NLAID)  
SO JOURNAL OF VIROLOGY, (1997 Mar) 71 (3) 2192-201.  
JN Journal code: KCV; 0113724. ISSN: 0022-538X.  
CY United States  
DT Journal Article (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199703  
ED Entered STN: 19970327  
Last Updated on STN: 19970327  
Entered Medline: 19970318

L16 ANSWER 2 OF 76 MEDLINE  
AN 92330820 MEDLINE  
DN 92330820 Pubmed ID: 1628125  
TI The role of recombinant cytokines and other immunomodulators on  
engraftment following allogeneic bone marrow transplantation in mice.  
AU Biedler A; Weiss L; Slavin S  
CS Department of Bone Marrow Transplantation, Hadassah University Hospital,  
Jerusalem, Israel.  
SO BONE MARROW TRANSPLANTATION, (1992 Jun) 9 (6) 421-6.  
JN Journal code: BON; 8702459. ISSN: 0268-3369.  
CY ENGLAND: United Kingdom  
DT Journal Article (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199208  
ED Entered STN: 19920904  
Last Updated on STN: 19920904  
Entered Medline: 19920820

L16 ANSWER 3 OF 76 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

AN 1999222808 EMBASE  
TI Anti-TNF strategies in Crohn's disease: Mechanisms, clinical effects,  
indications.

AU Baert F.; Rutgeerts P.R.  
CS P.R. Rutgeerts, Department of Gastroenterology, University Hospital  
Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.  
SO Paul.rutgeerts@kuleuven.ac.be  
International Journal of Colorectal Disease, (1999) 14(1) (47-51).  
Refs: 29

ISSN: 0179-1958 CODEN: IJOCDE6

CY Germany  
DT Journal Article  
FS 005 General Pathology and Pathological Anatomy  
026 Immunology, Serology and Transplantation  
029 Clinical Biochemistry  
030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
048 Gastroenterology  
LA English  
SL English

L16 ANSWER 4 OF 76 USPATFULL

AN 1999:159473 USPATFULL  
TI Method and compositions for solubilization and stabilization of  
polypeptides, especially proteins  
IN Hora, Maninder Singh, Rodeo, CA, United States  
Rubinfeld, Joseph, Danville, CA, United States  
Stern, Warren, Gainesville, FL, United States  
Wong, Gregory J., San Leandro, CA, United States  
Chilton Corporation, Emeryville, CA, United States (U.S. corporation)  
PI US 5997856  
PI US 1989-373928  
PI US 5997856  
RI US 1989-373928  
RI US 1989-373928 (7)  
DT now abandoned  
FS Utility  
IN.CNT 1523  
INCL INCLM: 424/085.200  
INCL INCLM: 514/002.000  
NCL INCLM: 424/085.200  
NCL NCLM: 514/002.000  
IC 16)  
ICM: A61K038-20  
ICS: A61K047-26  
EXF 424/85.2; 514/2; 514/12; 514/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 76 USPATFULL

AN 1999:154818 USPATFULL  
TI Method of treatment using electroporation mediated delivery of drugs and  
genes  
IN Dev, Sukhendu B., San Diego, CA, United States  
Hofmann, Gunter A., San Diego, CA, United States  
PA Genetronics, Inc., San Diego, CA, United States (U.S. corporation)  
PI US 5993434  
PI US 1995-537265  
RI US 1995-537265  
RI 19950929 (8)  
DT Continuation-in-part of Ser. No. US 1995-467566, filed on 6 Jun 1995,  
now patented, Pat. No. US 5702359, which is a continuation-in-part of  
Ser. No. US 1993-42039, filed on 1 Apr 1993, now patented, Pat. No. US  
5439440  
DT Utility

FS Granted  
LN.CNT 842  
INCL INCLM: 604/501.000  
NCL INCLM: 604/020.000; 604/021.000  
NCLM: 604/503.000  
NCLM: 604/020.000; 604/021.000  
IC [6]  
ICM: A61M031-00  
EXF 604/20-21; 604/49; 604/51; 604/501; 607/115-116; 435/173.6

L16 ANSWER 6 OF 76 USPATFULL  
AN 1999:146760 USPATFULL  
TI Phosphorylated fusion proteins  
IN Pestka, Sidney, North Caldwell, NJ, United States  
PA PBL Biomedical Laboratories, New Brunswick, NJ, United States (U.S. corporation)  
PI US 5986061 19991116  
AI US 1995-482087 19950607 (8)  
RLI Continuation of Ser. No. US 1995-375112, filed on 19 Jan 1995 which is a continuation of Ser. No. US 1993-156875, filed on 23 Nov 1993, now abandoned which is a continuation of Ser. No. US 1988-264271, filed on 28 Oct 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2596  
INCL INCLM: 530/352.000  
INCLM: 435/069.510; 435/071.200; 435/069.700; 435/471.000; 435/325.000; 435/252.300; 435/320.100; 536/023.400; 536/023.500; 536/023.520; 424/001.410; 424/001.490  
NCLM: 530/352.000  
NCLM: 435/069.510; 435/069.700; 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000; 536/023.400; 536/023.500; 536/023.520  
IC [6]  
ICM: C07K014-56  
ICS: C07K014-565; C12N015-62  
EXF 530/331; 530/352; 435/69.51; 435/71.1; 435/71.2; 435/69.7; 435/172.3; 435/325; 435/252.3; 435/320.1; 435/471.0; 536/23.4; 536/23.5; 536/23.52; 935/11; 935/22; 935/27; 935/66; 935/72; 424/1.41; 424/1.49  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 76 USPATFULL  
AN 1999:137464 USPATFULL  
TI Monoclonal antibody 1A7 and related polypeptides  
IN Chatterjee, Malaya, Lexington, KY, United States  
FOON, Kenneth A., Lexington, KY, United States  
Chatterjee, Sunil K., Lexington, KY, United States  
PA The Board of Trustees of the University of Kentucky, Lexington, KY, United States (U.S. corporation)  
PI US 5977316 19991102  
AI US 1996-591196 19960116 (8)  
RLI Continuation-in-part of Ser. No. US 1995-372676, filed on 17 Jan 1995, now patented, Pat. No. US 5612030  
DT Utility  
FS Granted  
LN.CNT 4578  
INCL INCLM: 530/387.200  
INCLM: 530/387.300; 530/387.700; 424/131.100; 424/133.300; 424/138.100  
NCLM: 530/387.200  
NCLM: 424/131.100; 424/133.100; 424/138.100; 530/387.300; 530/387.700  
IC [6]  
ICM: A61K039-395  
EXF 530/387.2; 530/387.3; 530/387.7; 424/131.1; 424/133.3; 424/138.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 76 USPATFULL  
AN 1999:128418 USPATFULL  
TI Nuclear cyclophilin  
IN Wang, Bruce, 1123 Banyan Way, Pacifica, CA, United States 94044  
Payan, Donald, 24 Windsor Dr., Hillsborough, CA, United States 94010  
Fisher, Joseph, 1035 S. Van Ness Ave., Apt. D, San Francisco, CA, United States 94110  
PI US 5968802 19991019  
AI US 1995-482728 19950607 (8)  
RLI Utility  
DT Utility  
FS Granted  
LN.CNT 1828  
INCL INCLM: 435/233.000  
INCLM: 435/252.300; 435/254.110; 435/320.100; 536/023.200  
NCLM: 435/233.000  
NCLM: 435/252.300; 435/254.110; 435/320.100; 536/023.200  
IC [6]  
ICM: C12N009-90  
ICS: C12N001-21; C12N015-63; C07H021-04  
EXF 435/233; 435/320.1; 435/252.3; 435/254.11; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 76 USPATFULL  
AN 1999:124868 USPATFULL  
TI Multivalent compounds for crosslinking receptors and uses thereof  
IN Bachovchin, William W., Melrose, MA, United States  
PA Trustees of Tufts College, Medford, MA, United States (U.S. corporation)  
PI US 5965532 19991012  
AI US 1997-837305 19970411 (8)  
RLI Continuation-in-part of Ser. No. US 1996-671756, filed on 28 Jun 1996, now abandoned  
DT Utility  
FS Granted  
LN.CNT 3884  
INCL INCLM: 514/012.000  
INCLM: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/323.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000  
NCLM: 514/012.000  
NCLM: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 530/323.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000  
IC [6]  
ICM: C07K005-00  
EXF 530/333-330; 514/12-18; 424/184.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 76 USPATFULL  
AN 1999:121379 USPATFULL  
TI Screening methods for cyclokinin inhibitors  
IN Mak, Vivian, Menlo Park, CA, United States  
PA Adolor Corporation, Malvern, PA, United States (U.S. corporation)  
PI US 5962477 19991005  
AI US 1998-97441 19980615 (9)  
RLI Continuation-in-part of Ser. No. WO 1995-US4677, filed on 11 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-400234, filed on 3 Mar 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-271287, filed on 6 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-225991, filed on 12 Apr 1994, now abandoned  
DT Utility  
FS Granted  
LN.CNT 5138  
INCL INCLM: 514/327.000





FS Granted  
LN.CNT 1255  
INCL INCLM: 435/235.100  
INCLM: 435/172.300; 435/069.600; 435/236.000; 424/093.200; 424/207.100  
NCLM: 435/235.100  
NCLM: 424/093.200; 424/207.100; 435/069.600; 435/236.000; 435/320.100;  
NCLM: 435/325.000; 435/366.000  
IC [6]  
ICM: C12N007-00  
ICS: C12N015-00; C12P021-04; A01N063-00  
435/172.3; 435/235.1; 435/69.6; 435/236; 424/93.2; 424/207.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 16 OF 76 USPTAFULL  
AN 1999:85264 USPTAFULL  
TI Vectors for gene delivery  
Eftathiou, Stacey, 18 Norwich Street, Cambridge, United Kingdom CB2  
1NE  
Ingilis, Stephen C., 2 Rhugarye Gardens, Linton, Cambridge, United Kingdom CB4 1AZ  
Kingdom, CB1 6LX  
PI Zhang, Xiaoliu, 21 Oak Tree Avenue, Cambridge, United Kingdom CB4 1AZ  
US 5928913 19990727  
AI US 1996-621501 19960325 (8)  
PRAI GB 1995-5892 19950323  
US 1995-29P 19950608 (60)  
DT Utility  
FS Granted  
LN.CNT 1536  
INCL INCLM: 435/172.300  
INCLM: 435/320.100; 435/372.300; 536/023.100; 536/023.500; 536/023.720  
NCLM: 435/457.000  
NCLM: 424/093.200; 435/320.100; 435/372.300; 536/023.100; 536/023.500;  
NCLM: 536/023.720  
IC [6]  
ICM: C12N015-63  
ICS: C12N005-08; C07H021-04  
424/93.21; 424/93.3; 424/204.1; 424/196.11; 424/225; 424/229.1;  
435/69.1; 435/91.33; 435/235.1; 435/240.2; 435/320.1; 435/172.3;  
435/372.3; 514/44; 514/806; 530/350; 530/806; 536/23.1; 536/23.5;  
536/23.72  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 76 USPTAFULL  
AN 1999:72572 USPTAFULL  
TI DNA transcription unit vaccines that protect against avian influenza  
viruses and methods of use thereof  
Webster, Robert, Memphis, TN, United States  
PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S. corporation)  
PI US 5916879 19990629  
AI US 1996-747286 19961112 (8)  
DT Utility  
FS Granted  
LN.CNT 1891  
INCL INCLM: 514/044.000  
INCLM: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;  
NCLM: 424/816.000  
NCLM: 514/044.000  
NCLM: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;  
NCLM: 536/023.720  
IC [6]  
ICM: A61K048-00  
ICS: C12N015-87; C12N015-44  
536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 76 USPTAFULL  
AN 1999:40232 USPTAFULL  
TI Myeloid cell leukemia associated gene MCL-1  
IN Craig, Ruth W., Hanover, NH, United States  
PA Dartmouth College, Hanover, NH, United States (U.S. corporation)  
PI US 5888812 19990330  
AI US 1995-441375 19950515 (8)  
RLI Division of Ser. No. US 1993-77848, filed on 16 Jun 1993, now patented, Pat. No. US 5476955 which is a continuation-in-part of Ser. No. US 1993-12307, filed on 2 Feb 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1485  
INCL INCLM: 435/325.000  
INCLM: 435/006.000; 435/007.230; 435/320.100; 435/235.100; 435/172.300;  
530/387.700; 530/388.800; 536/023.500; 536/023.100; 935/006.000;  
935/032.000; 935/034.000; 935/055.000; 935/057.000; 935/070.000;  
935/071.000; 424/450.000  
NCLM: 435/325.000  
NCLM: 424/450.000; 435/006.000; 435/007.230; 435/235.100; 435/320.100;  
NCLM: 530/387.700; 530/388.800; 536/023.100; 536/023.500  
IC [6]  
ICM: C07H021-00  
ICS: 536/23.1; 536/23.5; 435/6; 435/7.23; 435/325; 435/320.1; 435/172.3;  
435/235.1; 530/387.7; 935/24; 935/55; 935/66; 935/70; 935/71; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 76 USPTAFULL  
AN 1999:24756 USPTAFULL  
TI Antibodies to nuclear matrix proteins  
IN Coffey, Donald S., Lutherville, MD, United States  
Partin, Alan W., Baltimore, MD, United States  
Getzenberg, Robert H., Branford, CT, United States  
PA The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)  
PI US 5874539 19990223  
AI US 1995-458023 19950602 (8)  
RLI Division of Ser. No. US 1993-15624, filed on 9 Feb 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1519  
INCL INCLM: 530/387.100  
INCLM: 530/387.700; 530/388.100  
NCLM: 530/387.100  
NCLM: 530/387.700; 530/388.100  
IC [6]  
ICM: C07K016-18  
ICS: 530/358; 530/388.15; 530/403; 530/828; 530/850; 530/854;  
530/387.7; 530/387.1; 530/388.1; 435/69.3; 424/138.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 76 USPTAFULL  
AN 1999:21711 USPTAFULL  
TI CXG chemokines as regulators of angiogenesis  
IN Strieter, Robert M., Ann Arbor, MI, United States  
Polverini, Peter J., Ann Arbor, MI, United States  
Kunkel, Steven L., Ann Arbor, MI, United States  
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)  
PI US 5871723 19990216  
AI US 1995-468819 19950606 (8)  
DT Utility

FS Granted  
LN CNT 6055  
INCL INCLM: 424/085.100  
INCLS: 514/002.000; 514/008.000; 514/012.000  
NCLM: 424/085.100  
NCL NCLS: 514/002.000; 514/008.000; 514/012.000  
IC [6]  
ICM: A61K038-19  
EXF 424/85.1; 514/2; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L16 ANSWER 21 OF 76 USPTFULL  
AN 1999:15889 USPTFULL  
TI Bladder nuclear matrix proteins, polynucleotide sequences encoding them,  
and their use  
IN Getzenberg, Robert H., Pittsburgh, PA, United States  
Bahson, Robert H., Pittsburgh, PA, United States  
PA University of Pittsburgh, Pittsburgh, PA, United States (U.S.  
corporation)  
PI US 5866535 19980202  
AI US 1996-742850 19961101 (8)  
PRAI US 1995-6626P 19951103 (60)  
DT Utility  
FS Granted  
LN CNT 904  
INCL INCLM: 514/002.000  
INCLS: 530/350.000; 530/300.000  
NCLM: 514/002.000  
NCL NCLS: 530/300.000; 530/350.000  
IC [6]  
ICM: C07K014-00  
EXF 530/350; 530/300; 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L16 ANSWER 22 OF 76 USPTFULL  
AN 1998:157496 USPTFULL  
TI CD40 coding sequences  
IN Seed, Brian, Boston, MA, United States  
Allen, Janet, Glasgow, Scotland  
Aruffo, Alejandro, Edmonds, WA, United States  
Camerini, David, Charlottesville, VA, United States  
Lautner, Leander, Gladenbach, Germany, Federal Republic of  
Oquendo, Carmen, Gladenbach, Germany, Federal Republic of  
Simmons, David, Headington, United Kingdom  
Stamenkovic, Ivan, Winchester, MA, United States  
Stengelin, Siegfried, Epstein, Germany, Federal Republic of  
Amiot, Martine, Nantes, France  
PA The General Hospital Corporation, Charlestown, MA, United States (U.S.  
corporation)  
PI US 5849898 19981215  
AI US 1995-485447 19950607 (8)  
RLI Division of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a  
continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990,  
now abandoned which is a continuation-in-part of Ser. No. US  
1990-498809, filed on 23 Mar 1990, now abandoned which is a  
continuation-in-part of Ser. No. US 1989-379076, filed on 13 Jul 1989,  
now abandoned which is a continuation-in-part of Ser. No. US  
1988-160416, filed on 25 Feb 1988, now abandoned  
DT Utility  
FS Granted  
LN CNT 3541  
INCL INCLM: 536/023.500  
INCLS: 435/069.100; 435/257.300; 435/320.100  
NCL NCLM: 536/023.500

IC NCLS: 435/069.100; 435/257.300; 435/320.100  
[6]  
EXF 536/23.5; 435/69.1; 435/252.3; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L16 ANSWER 23 OF 76 USPTFULL  
AN 1998:157126 USPTFULL  
TI Nuclear matrix proteins  
IN Coffey, Donald S., Lutherville, MD, United States  
Partin, Alan W., Baltimore, MD, United States  
Getzenberg, Robert H., Branford, MD, United States  
PA The Johns Hopkins University School of Medicine, Baltimore, MD, United  
States (U.S. corporation)  
PI US 5849509 19981215  
AI US 1995-488036 19950607 (8)  
RLI Division of Ser. No. US 1993-15624, filed on 9 Feb 1993, now abandoned  
DT Utility  
FS Granted  
LN CNT 1514  
INCL INCLM: 435/007.230  
INCLS: 435/007.100; 436/064.000; 436/813.000  
NCLM: 435/007.230  
NCL NCLS: 435/007.100; 436/064.000; 436/813.000  
IC [6]  
ICM: G01N033-574  
EXF 435/7.1; 435/7.23; 530/388.1; 436/64; 436/813  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L16 ANSWER 24 OF 76 USPTFULL  
AN 1998:154116 USPTFULL  
TI Fungal Protease  
IN Buxton, Frank, Holderstudeilweg 32, 4132 Muttenz, Switzerland  
Hinzen, Albert, Am Planetarium 32, 07743 Jena, Germany, Federal Republic  
of  
PI US 5846802 19981208 (8)  
AI US 1994-225488 19940408 (8)  
RLI Continuation-in-part of Ser. No. US 1993-47214, filed on 13 Apr 1993,  
now abandoned  
PRAI GB 1992-810281 19920415  
GB 1993-5097 19930312  
DT Utility  
FS Granted  
LN CNT 2659  
INCL INCLM: 435/225.000  
INCLS: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;  
435/014.000; 435/028.000; 435/068.000; 536/023.200  
NCLM: 435/225.000  
NCL NCLS: 435/069.100; 435/091.100; 435/254.110; 435/254.300; 435/320.100;  
536/023.200  
IC [6]  
ICM: C12N015-57  
EXF 435/225; 435/69.1; 435/172.3; 435/252.3; 435/254.3; 435/320.1;  
536/252.3; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L16 ANSWER 25 OF 76 USPTFULL  
AN 1998:150739 USPTFULL  
TI Alphavirus vector constructs  
IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States  
Polo, John M., San Diego, CA, United States

Ibanez, Carlos E., San Diego, CA, United States  
 Chang, Stephen M. W., San Diego, CA, United States  
 Jolly, Douglas J., Leucadia, CA, United States  
 Driver, David A., San Diego, CA, United States  
 Belli, Barbara A., San Diego, CA, United States  
 Chicon Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 5843723 19981201  
 AI US 1996-739167 19961030 (8)  
 RLI Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-122791, filed on 15 Sep 1993, now abandoned  
 Utility  
 FS Granted  
 DT 10318  
 LN CNT 10318  
 INCL INCLM: 435/069.300  
 INCLS: 435/320.100; 435/325.000; 435/235.100  
 NCL NCLM: 435/069.300  
 NCLS: 435/235.100; 435/320.100; 435/325.000  
 IC [6]  
 ICM: C12P021-02  
 ICS: C12N015-63; C12N005-10  
 EXF 435/320.1; 435/325; 435/69.3; 435/235.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 26 OF 76 USPATFULL  
 AN 1998:144236 USPATFULL  
 TI NF-AT polypeptides and polynucleotides  
 IN Crabtree, Gerald R., Woodside, CA, United States  
 Northrop, Jeffrey P., Campbell, CA, United States  
 Board of Trustees of Ireland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)  
 PI US 5837840 19981117  
 AI US 1993-124981 19930920 (8)  
 DT Utility  
 FS Granted  
 LN CNT 2291  
 INCL INCLM: 536/023.400  
 INCLS: 536/023.100; 536/024.300  
 NCL NCLM: 536/023.400  
 NCLS: 536/023.100; 536/024.300  
 IC [6]  
 ICM: C07H021-04  
 EXF 530/350; 435/69.1; 435/320.1; 435/240.2; 536/23.1; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 27 OF 76 USPATFULL  
 AN 1998:134881 USPATFULL  
 TI Cloning vector, polylinker and methods  
 IN Seed, Brian, Boston, MA, United States  
 Aruffo, Alejandro, Edmonds, WA, United States  
 The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)  
 PI US 5830731 19981103  
 AI US 1997-861205 19970521 (8)  
 RLI Continuation of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990, now abandoned which is a continuation of Ser. No. US 1989-379076, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160416, filed on 25 Feb 1988, now abandoned  
 Utility  
 DT

FS Granted  
 LN CNT 3587  
 INCL INCLM: 435/172.300  
 INCLS: 435/252.300; 435/320.100; 536/024.200  
 NCL NCLM: 435/091.910  
 NCLS: 435/252.300; 435/320.100; 536/024.200  
 IC [6]  
 ICM: C12N015-66  
 EXF 435/252.7; 435/320.1; 435/172.3; 536/24.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 28 OF 76 USPATFULL  
 AN 1998:134627 USPATFULL  
 TI Yeast-based delivery vehicles  
 IN Duke, Richard C., Denver, CO, United States  
 Franzusoff, Alex, Boulder, CO, United States  
 Bellgrau, Donald, Denver, CO, United States  
 University Technology Corporation, Boulder, CO, United States (U.S. corporation)  
 PI US 5830463 19981103  
 AI US 1994-340185 19941115 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-88322, filed on 7 Jul 1993, now patented, Pat. No. US 5413914  
 Utility  
 FS Granted  
 DT 1929  
 LN CNT 1929  
 INCL INCLM: 424/093.510  
 INCLS: 424/093.500; 424/093.200; 435/320.100; 435/375.000; 435/172.300; 435/069.100  
 NCL NCLM: 424/093.510  
 NCLS: 424/093.200; 424/093.500; 435/069.100; 435/320.100; 435/375.000  
 IC [6]  
 ICM: C12N015-00  
 EXF 435/320.1; 435/240.2; 435/6; 435/7.1; 435/172.3; 435/7.2; 435/7.31; 514/44; 935/62; 935/52; 935/55; 935/56; 935/57; 935/32; 424/93.1; 424/93.2; 424/93.21; 424/93.51; 424/93.5; 536/23.74  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 29 OF 76 USPATFULL  
 AN 1998:128084 USPATFULL  
 TI Method for detecting prostate cancer using a reagent which binds prostate cancer-1 protein  
 IN Coffey, Donald S., Lutherville, MD, United States  
 Partin, Alan W., Baltimore, MD, United States  
 Getzenberg, Robert H., Pittsburgh, PA, United States  
 The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)  
 PI US 5824490 19981020  
 AI US 1995-455558 19950531 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-15624, filed on 9 Feb 1993, now abandoned  
 Utility  
 FS Granted  
 DT 1572  
 LN CNT 1572  
 INCL INCLM: 435/007.230  
 INCLS: 435/007.100; 436/064.000; 436/813.000  
 NCL NCLM: 435/007.230  
 NCLS: 435/007.100; 436/064.000; 436/813.000  
 IC [6]  
 ICM: G01N033-574  
 EXF 435/7.1; 435/7.23; 530/387.1; 530/388.1; 436/64; 436/813  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 30 OF 76 USPTAFULL  
 AN 1998:119004 USPTAFULL  
 TI Eukaryotic layered vector initiation systems  
 IN Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Santa Fe, CA, United States 92024  
 Polio, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States 92109  
 Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024  
 Driver, David A., 5142 Baltimore St., San Diego, CA, United States 92117  
 PI US 5814482 19980929 (8)  
 AI US 1996-739158  
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 10431  
 INCL INCLM: 435/069.300  
 INCLM: 435/320.100; 536/023.100; 536/024.100  
 NCLM: 435/069.300  
 NCL NCLM: 435/320.100; 536/023.100; 536/024.100  
 IC [6]  
 ICM: C12P021-00  
 ICS: C12N015-86; C07H021-04  
 EXF 435/69.3; 435/320.1; 536/23.1; 536/24.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 31 OF 76 USPTAFULL  
 AN 1998:108036 USPTAFULL  
 TI Recombinant canine herpesviruses  
 IN Haanes, Elizabeth J., Berthoud, CO, United States  
 Frank, Rexann S., Wellington, CO, United States  
 Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)  
 PI US 5804197 19980908  
 AI US 1996-680726 19960712 (8)  
 RLI Continuation-in-part of Ser. No. US 1996-602010, filed on 15 Feb 1996  
 DT Utility  
 FS Granted  
 LN.CNT 5536  
 INCL INCLM: 424/229.100  
 INCLM: 424/199.100; 435/235.100; 435/320.100  
 NCLM: 424/229.100  
 NCL NCLM: 424/199.100; 435/235.100; 435/320.100  
 IC [6]  
 ICM: A61K039-245  
 ICS: A61K039-00; C12N007-01; C12N015-00  
 EXF 424/229.1; 424/199.1; 435/235.1; 435/320.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 32 OF 76 USPTAFULL  
 AN 1998:91872 USPTAFULL  
 TI Alphavirus structural protein expression cassettes  
 IN Dubensky, Jr., Thomas W., Rancho Santa Fe, CA, United States  
 Polio, John M., San Diego, CA, United States  
 Ibanez, Carlos E., San Diego, CA, United States  
 Chang, Stephen M., W., San Diego, CA, United States  
 Jolly, Douglas J., Leucadia, CA, United States  
 Driver, David A., San Diego, CA, United States  
 PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

PI US 5789245 19980804  
 AI US 1996-741881 19961030 (8)  
 RLI Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 10270  
 INCL INCLM: 435/320.100  
 INCLM: 435/691.000; 435/325.000; 536/023.720  
 NCLM: 435/320.100  
 NCL NCLM: 435/069.100; 435/325.000; 536/023.720  
 IC [6]  
 ICM: C12N015-63  
 ICS: C12N015-40; C12N005-10; C12P021-02  
 EXF 435/320.1; 435/69.1; 435/325; 536/23.72  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 33 OF 76 USPTAFULL  
 AN 1998:79186 USPTAFULL  
 TI Use of quinoxaline-3-carboxamide compounds for inhibiting the production of tumor necrosis factor (TNF) and/or for the treatment of septic shock  
 IN Kroemer, Guido Peter, Madrid, Spain  
 Gonzalez, Joseangel, Madrid, Spain  
 Alonso, Carlos Martinez, Madrid, Spain  
 Kalland, Terje, Loddekoping, Sweden  
 Pharmacia AB, Stockholm, Sweden (non-U.S. corporation)  
 PI US 5776947 19980707  
 AI WO 9503051 19950202  
 WO 9503051 19960520 (8)  
 WO 1994-SE565 19940610  
 19960520 PCT 371 date  
 19960520 PCT 102(e) date  
 PRAI SE 1993-2490 19930726  
 DT Utility  
 FS Granted  
 LN.CNT 535  
 INCL INCLM: 514/312.000  
 INCLM: 514/313.000  
 NCLM: 514/312.000  
 NCL NCLM: 514/313.000  
 IC [6]  
 ICM: A61K031-47  
 ICS: 514/312; 514/313  
 EXF 514/312; 514/313  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L16 ANSWER 34 OF 76 USPTAFULL  
 AN 1998:69157 USPTAFULL  
 TI Afamin: a human serum albumin-like protein  
 IN Lichenstein, Henri Stephen, Ventura, CA, United States  
 Lyons, David Edwin, Thousand Oaks, CA, United States  
 Wufte, Mark Matsuo, New York, NY, United States  
 Wright, Samuel Donald, Larchmont, NY, United States  
 Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
 PA The Rockefeller University, New York, NY, United States (U.S. corporation)  
 PI US 5767243 19980616  
 AI US 1997-816920 19970313 (8)  
 RLI Division of Ser. No. US 1994-222619, filed on 31 Mar 1994, now patented, Pat. No. US 5652352

DT Utility  
 FS Granted  
 LN.CNT 1863  
 INCL INCLM: 530/350.000  
 NCL NCLM: 530/350.000  
 IC [6]  
 ICM: C07K013-00  
 530/350; 530/387.1  
 EXF 530/350; 530/387.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 76 USPTAFULL  
 AN 1998:68822 USPTAFULL  
 TI Cysteine-pegylated proteins  
 IN Braxton, Scott M., San Mateo, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5766897 19980616  
 AI US 1995-427100 19950421 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-144758, filed on 29 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-924294, filed on 3 Aug 1992, now patented, Pat. No. US 5457090 which is a continuation of Ser. No. US 1990-542484, filed on 21 Jun 1990, now patented, Pat. No. US 5187089, issued on 16 Feb 1993

DT Utility  
 FS Granted  
 LN.CNT 2765  
 INCL INCLM: 435/172.100  
 INCLS: 435/188.000; 435/212.000; 435/219.000  
 NCL NCLM: 435/463.000  
 NCLS: 435/188.000; 435/212.000; 435/219.000  
 IC [6]  
 ICM: C12N015-00  
 ICS: C12N009-96; C12N009-48; C12N009-50  
 EXF 514/12; 530/350; 435/69.2; 435/188; 435/172.1; 435/212; 435/219  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 76 USPTAFULL  
 AN 1998:65353 USPTAFULL  
 TI HIV-specific synthetic antigens and their use  
 IN Conley, Anthony J., Exton, PA, United States  
 PA Arnold, Beth A., Quakertown, PA, United States  
 PI Koller, Lynn J., Lansdale, PA, United States  
 PI Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 AI US 5763574 19980609  
 RLI US 1996-625691 19960404 (8)  
 Continuation of Ser. No. US 1994-323338, filed on 14 Oct 1994, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 1123  
 INCL INCLM: 530/326.000  
 INCLS: 530/350.000; 530/395.000; 424/188.100; 424/184.100; 424/208.100;  
 NCL NCLM: 424/204.100  
 NCLS: 530/326.000  
 NCLS: 424/184.100; 424/188.100; 424/204.100; 424/208.100; 530/350.000;  
 530/395.000

IC [6]  
 ICM: A61K038-00  
 ICS: A61K039-21; C07K005-00; C07K007-00  
 EXF 424/188.1; 424/184.1; 424/204.1; 530/350; 530/395  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 37 OF 76 USPTAFULL

AN 1998:57762 USPTAFULL  
 TI Aspergillus niger vacuolar aspartyl protease  
 IN Buxton, Frank, Murtens, Switzerland  
 PA Jarek, Gabor, Oberwil, Switzerland  
 PI Wiser, Uscod, Wengenigen, Netherlands  
 PI Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
 AI US 5756338 19980526  
 RLI US 1996-731045 19961008 (8)  
 Division of Ser. No. US 1994-32831M, filed on 24 Oct 1994, now patented, Pat. No. US 5674728, issued on 7 Oct 1997

DT Utility  
 FS Granted  
 LN.CNT 1957  
 INCL INCLM: 435/219.000  
 INCLS: 435/254.300; 536/023.200  
 NCL NCLM: 435/219.000  
 NCLS: 435/254.300; 536/023.200  
 IC [6]  
 ICM: C12N009-62  
 ICS: C12N015-57; C12N015-63; C12N015-80  
 EXF 435/219; 435/254.3; 435/2; 536/23.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 38 OF 76 USPTAFULL  
 AN 1998:54490 USPTAFULL  
 TI Recombinant canine herpesviruses  
 IN Hannes, Elizabeth J., Boulder, CO, United States  
 PA Frank, Rexam S., Wellington, CO, United States  
 PI Hesk Corporation, Ft. Collins, CO, United States (U.S. corporation)  
 AI US 5753235 19980519  
 RLI US 1996-602010 19960215 (8)  
 Utility

DT Utility  
 FS Granted  
 LN.CNT 3143  
 INCL INCLM: 424/229.100  
 INCLS: 424/147.100; 435/235.100; 530/388.300; 530/395.000  
 NCL NCLM: 424/229.100  
 NCLS: 424/147.100; 435/235.100; 530/388.300; 530/395.000  
 IC [6]  
 ICM: A61K039-245  
 ICS: C12N007-01; C07K001-00; C12P021-02  
 EXF 424/229.1; 424/147.1; 435/235.1; 530/388.3; 530/395  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 39 OF 76 USPTAFULL  
 AN 1998:36744 USPTAFULL  
 TI Method for treating vascular leak syndrome  
 IN Siegall, Clay, Seattle, WA, United States  
 PA Chace, Dana, Seattle, WA, United States  
 PI Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)  
 PI US 5736536 19980407  
 AI US 1997-795751 19970206 (8)  
 RLI Division of Ser. No. US 1994-253351, filed on 19 Aug 1994

DT Utility  
 FS Granted  
 LN.CNT 696  
 INCL INCLM: 514/165.000  
 INCLS: 514/228.500; 514/420.000; 514/568.000; 514/561.000; 514/570.000  
 NCL NCLM: 514/165.000  
 NCLS: 514/228.500; 514/420.000; 514/568.000; 514/569.000; 514/570.000  
 IC [6]  
 ICM: A61K031-60

ICS: A61K061-54; A61K031-54  
 EXF 514/226.5; 514/420; 514/568; 514/569; 514/570; 514/165  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 40 OF 76. USPATFULL  
 AN 1998:30684 USPATFULL  
 TI Method and compositions for solubilization and stabilization of  
 IN polypeptides, especially proteins  
 AI Hora, Maninder Singh, Rodeo, CA, United States  
 AI Rubinfield, Joseph, Danville, CA, United States  
 AI Stern, Warren, Gainesville, FL, United States  
 AI Wong, Gregory J., San Leandro, CA, United States  
 PA Chilton Corporation, Emeryville, CA, United States (U.S. corporation)  
 PI US 5730969 19980324  
 AI US 1995-474178 19950607 (8)  
 RLI Division of Ser. No. US 1989-373928, filed on 29 Jun 1989 which is a  
 continuation-in-part of Ser. No. US 1988-253720, filed on 5 Oct 1988,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1753  
 INCL INCLM: 424/085.100  
 INCLS: 424/085.200; 424/085.400; 424/085.600; 424/094.300; 514/002.000;  
 514/003.000; 514/012.000; 514/021.000  
 NCL NCIM: 424/085.100  
 NCLS: 424/085.200; 424/085.400; 424/085.600; 424/094.300; 514/002.000;  
 514/003.000; 514/012.000; 514/021.000  
 IC (6)  
 ICM: A61K038-17  
 ICS: A61K038-19; A61K038-20; A61K038-49  
 EXF 435/188; 424/85.1; 424/85.2; 424/85.4; 424/85.5; 424/85.6; 424/85.7;  
 424/94.3; 530/303; 530/351; 530/399; 514/2; 514/3; 514/12; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 41 OF 76. USPATFULL  
 AN 1998:28183 USPATFULL  
 TI Use of cyclohextrins for protein renaturation  
 IN Sharma, Ajit, Mount Pleasant, MI, United States  
 PA Karupiah Nadarajah, Mount Pleasant, MI, United States  
 PA Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.  
 corporation)  
 PI US 5728804 19980317  
 AI US 1995-460234 19950602 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 672  
 INCL INCLM: 530/350.000  
 INCLS: 530/351.000; 530/399.000; 530/414.000; 530/417.000; 514/021.000;  
 435/069.100; 435/069.400; 435/069.500; 435/158.000  
 NCL NCIM: 530/350.000  
 NCLS: 435/069.100; 435/069.400; 435/069.500; 435/188.000; 530/351.000;  
 530/399.000; 530/414.000; 530/417.000  
 IC (6)  
 ICM: C07K001-00  
 ICS: C12P021-06  
 EXF 530/350; 530/351; 530/399; 530/414; 530/417; 514/21; 435/69.1; 435/69.4;  
 435/69.5; 435/188  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 42 OF 76. USPATFULL  
 AN 1998:27762 USPATFULL  
 TI Methods and compositions incorporating IP-10  
 IN Sarits, Andreas H., Houston, TX, United States  
 IN Broxmeyer, Hal E., Indianapolis, IN, United States

PA Ravetch, Jeff V., New York, NY, United States  
 Board of Regents, The University of Texas System, Austin, TX, United  
 States (U.S. corporation)  
 IN Indiana University Foundation, Bloomington, IN, United States (U.S.  
 corporation)  
 AI Sloan-Rettering Institute for Cancer Research, New York, NY, United  
 States (U.S. corporation)  
 PI US 5728377 19980317  
 AI US 1993-94851 19930720 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1630  
 INCL INCLM: 424/085.100  
 INCLS: 435/069.500; 530/351.000  
 NCL NCIM: 424/085.100  
 NCLS: 435/069.500; 530/351.000  
 IC (6)  
 ICM: A61K045-05  
 EXF 424/85.1; 435/69.5; 530/351; 935/13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 43 OF 76. USPATFULL  
 AN 1998:11702 USPATFULL  
 TI Hybrid immunoglobulins  
 IN Capon, Daniel J., San Mateo, CA, United States  
 IN Lasky, Laurence A., Sausalito, CA, United States  
 PA Genentech Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 PI US 5714147 19980203  
 AI US 1995-451848 19950526 (8)  
 RLI Continuation of Ser. No. US 1994-185670, filed on 21 Jan 1994, now  
 patented, Pat. No. US 5514582 which is a continuation of Ser. No. US  
 1992-986931, filed on 8 Dec 1992, now patented, Pat. No. US 5428130  
 which is a continuation of Ser. No. US 1991-808122, filed on 19 Dec  
 1991, now patented, Pat. No. US 5225938 which is a division of Ser. No.  
 US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964  
 which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23  
 Feb 1989, now patented, Pat. No. US 5098533  
 DT Utility  
 FS Granted  
 LN.CNT 2709  
 INCL INCLM: 424/178.100  
 INCLS: 435/697.000; 530/387.100; 536/023.400  
 NCL NCIM: 424/178.100  
 NCLS: 435/069.700; 530/387.100; 536/023.700  
 IC (6)  
 ICM: A61K039-395  
 EXF 435/69.7; 514/2; 530/35; 530/387.1; 536/23.4; 424/178.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 44 OF 76. USPATFULL  
 AN 97:114931 USPATFULL  
 TI Modified anti-TCM-1 antibodies and their use in the treatment of  
 IN inflammation  
 IN Faanes, Ronald Bertrand, Pound Ridge, NY, United States  
 IN McGoff, Paul Edward, Watertown, CT, United States  
 IN Shirley, Bret Allen, New Milford, CT, United States  
 PA Scher, David Stuart, Danbury, CT, United States  
 PA Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United  
 States (U.S. corporation)  
 PI US 5695760 19971209  
 AI US 1995-427355 19950424 (8)  
 DT Utility  
 FS Granted

LN.CNT 3085  
INCL INCLM: 424/178.100  
INCL: 424/181.100; 530/391.100; 530/388.850  
NCLM: 424/178.100  
NCL: 424/181.100; 530/388.850; 530/391.100  
IC [6]  
ICM: A61K039-395  
ICS: C07K016-28  
EXF 530/391.1; 530/388.85; 424/181.1; 424/178.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 45 OF 76 USPTFULL  
AN 97:112357 USPTFULL  
TI Anti-cancer immunotherapeutics  
IN Chada, Sunil, Vista, CA, United States  
Bodner, Mordechai, San Diego, CA, United States  
Jolly, Douglas J., La Jolla, CA, United States  
Barber, Jack R., San Diego, CA, United States  
DeJesus, Cary E., San Diego, CA, United States  
Chilton Viagene, Inc., United States (U.S. corporation)  
PI US 5693522  
PI 19971202  
PI 19950111 (8)  
R1 Continuation of Ser. No. US 1993-104424, filed on 9 Aug 1993, now abandoned which is a continuation of Ser. No. US 1991-800328, filed on 29 Nov 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1669  
INCL INCLM: 435/002.402  
INCL: 435/172.300; 435/320.100; 536/023.100  
NCLM: 435/325.000  
NCL: 435/320.100; 435/350.000; 435/353.000; 435/357.000; 435/364.000; 435/366.000; 536/023.100  
IC [6]  
ICM: C12N015-00  
ICS: C12N005-00; C07H021-02  
EXF 435/320.1; 435/172.3; 435/240.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 46 OF 76 USPTFULL  
AN 97:107067 USPTFULL  
TI Method for treating vascular leak syndrome  
IN Siegall, Clay, Seattle, WA, United States  
Chace, Dana, Seattle, WA, United States  
Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)  
PI US 5688781  
PI 19971118  
PI 19940819 (8)  
AI US 1994-293351  
DT Utility  
FS Granted  
LN.CNT 814  
INCL INCLM: 514/179.000  
NCLM: 514/179.000  
NCL [6]  
ICM: A61K031-56  
EXF 514/179  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 47 OF 76 USPTFULL  
AN 97:99018 USPTFULL  
TI Lymphokine gene therapy of cancer  
IN Sobol, Robert E., La Jolla, CA, United States  
Gage, Fred H., La Jolla, CA, United States  
Royston, Ivor, La Jolla, CA, United States

PA Friedman, Theodore, La Jolla, CA, United States  
Fakhrai, Habib, Oceanside, CA, United States  
Sidney Kimmel Cancer Center, San Diego, CA, United States (U.S. corporation)  
PI US 5685563  
PI 19971028  
PI 19941209 (8)  
R1 Continuation of Ser. No. US 1992-863641, filed on 3 Apr 1992, now abandoned Continuation-in-part of Ser. No. US 1991-781356, filed on 25 Oct 1991, now abandoned Continuation-in-part of Ser. No. US 1991-720872, filed on 25 Jun 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 2156  
INCL INCLM: 424/093.210  
INCL: 435/240.200; 435/320.100; 435/172.300; 435/069.500; 424/184.100; 424/277.100  
NCLM: 424/093.210  
NCL: 424/184.100; 424/277.100; 435/069.500; 435/320.100  
IC [6]  
ICM: A61K048-00  
ICS: A61K039-00; C12N005-00  
EXF 435/69.1; 435/69.5; 435/69.51; 435/69.52; 435/69.3; 435/320.1; 435/240.2; 435/172.3; 435/7.2; 530/350; 530/351; 514/44; 514/12; 424/85.1; 424/85.5; 424/85.2; 424/93.21; 424/93; 935/62; 935/52; 935/57; 935/32; 935/66; 935/70; 935/71; 935/33; 935/34; 935/65  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 48 OF 76 USPTFULL  
AN 97:91390 USPTFULL  
TI Aspergillus niger vacuolar aspartyl protease  
IN Buxton, Frank, Nutten, Switzerland  
Jara, Gabor, Oberwil, Switzerland  
Visser, Jacob, Wageningen, Netherlands  
PA Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
PI US 5674728  
PI 19971007  
PI 19941024 (8)  
PRAI EP 1993-810764  
PRAI 19931103  
DT Utility  
FS Granted  
LN.CNT 2018  
INCL INCLM: 435/225.000  
INCL: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/172.300; 435/320.100; 536/023.200  
NCLM: 435/225.000  
NCL: 435/069.100; 435/252.300; 435/254.110; 435/254.300; 435/320.100; 435/477.000; 435/488.000; 536/023.200  
IC [6]  
ICM: C12N015-58  
ICS: C12N015-80; C12N009-62  
EXF 435/219; 435/223; 435/225; 435/252.3; 435/254.11; 435/254.3; 435/172.3; 435/320.1; 435/69.1; 536/23.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 49 OF 76 USPTFULL  
AN 97:66235 USPTFULL  
TI A human serum albumin-like gene  
IN Lichenstein, Henri Stephen, Ventura, CA, United States  
Lyons, David Edwin, Thousand Oaks, CA, United States  
Wurfel, Mark Matsuo, New York, NY, United States  
Wright, Samuel Donald, Larchmont, NY, United States  
PA Angen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
The Rockefeller University, New York, NY, United States (U.S. corporation)  
PI US 5652352  
PI 19970729

AI US 1994-2222619 19940331 (8)  
 DT Utility  
 FS Granted  
 LN CNT 1870  
 INCL INCLM: 536/023.500  
 NCL INCLS: 536/023.100; 435/069.100  
 NCLM: 536/023.500  
 NCLS: 435/069.100; 536/023.100  
 IC (6)  
 ICM: C07H021-02  
 ICS: C07H021-04; C12P021-00  
 EXF 435/6; 435/320.1; 435/69.1; 536/23.1; 536/23.5; 536/24.3; 536/23.2;  
 536/24.5; 514/44  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 50 OF 76 USPTAFULL  
 AN 97:49543 USPTAFULL  
 TI Carcinoma associated antigen (SKI) monoclonal antibodies against SKI,  
 methods of producing these antibodies and use thereof  
 IN Classy, Mark C., San Diego, CA, United States  
 Chang, Helena R., Providence, RI, United States  
 Kodra, Keiji, Chiba, Japan  
 Sci-Clone, Inc., San Diego, CA, United States (U.S. corporation)  
 PA The Regents of the University of California, Oakland, CA, United States  
 PI US 5637493 19970610  
 AI US 1994-201243 19940224 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-82717, filed on 29 Jan 1992,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN CNT 1245  
 INCL INCLM: 435/327.000  
 INCLS: 530/388.800; 530/388.850; 530/387.200; 530/388.150; 935/100.000;  
 NCLM: 435/327.000  
 NCLS: 435/344.100  
 IC (6)  
 ICM: C07K016-30  
 ICS: C07K016-42; C12N005-12  
 EXF 435/240.27; 530/387.2; 530/388.15; 530/388.8; 530/388.85; 935/100  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 51 OF 76 USPTAFULL  
 AN 97:29374 USPTAFULL  
 TI Oncostatin M and novel compositions having anti-neoplastic activity  
 IN Zarling, Joyce M., Seattle, WA, United States  
 Marquardt, Hans, Mercer Island, WA, United States  
 Hanson, Marcia B., Seattle, WA, United States  
 Malik, Najma, Seattle, WA, United States  
 Linsley, Peter S., Seattle, WA, United States  
 Rose, Timothy M., Seattle, WA, United States  
 PA Purcino, Anthony F., Seattle, WA, United States  
 Oncogen Limited Partnership, Seattle, WA, United States (U.S.  
 corporation)  
 PI US 5618715 19970408  
 AI US 1993-75199 19930610 (8)  
 RLI Continuation of Ser. No. US 1991-689723, filed on 22 Apr 1991, now  
 abandoned which is a continuation of Ser. No. US 1988-144574, filed on  
 15 Jan 1988, now abandoned which is a continuation-in-part of Ser. No.  
 US 1987-15139, filed on 30 Oct 1987, now abandoned which is a  
 continuation-in-part of Ser. No. US 1987-46846, filed on 4 May 1987, now  
 patented, Pat. No. US 5120535, issued on 9 Jun 1992 which is a

DT continuation-in-part of Ser. No. US 1986-935283, filed on 26 Nov 1986,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1985-811235, filed on 20 Dec 1985, now abandoned  
 FS Utility  
 LN CNT 2185  
 INCL INCLM: 435/325.000  
 INCLS: 435/069.100; 435/069.400; 435/320.100; 435/348.000; 435/360.000;  
 435/365.100; 435/364.000; 536/023.100; 536/023.510; 530/300.000;  
 NCLM: 435/325.000  
 NCLS: 435/069.100; 435/069.400; 435/320.100; 435/348.000; 435/360.000;  
 435/364.000; 435/365.100; 536/300.000; 530/351.000; 536/023.100;  
 536/023.510  
 IC (6)  
 ICM: C12N005-00  
 ICS: C12N015-00; C12P021-06; C07H017-00  
 EXF 530/300; 530/351; 536/23.1; 536/23.4; 435/320.1; 435/69.1; 435/69.4;  
 435/69.8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 52 OF 76 USPTAFULL  
 AN 97:29349 USPTAFULL  
 TI Method of using an ER-located endoprotease  
 IN Chaudhuri, Bhabatosh, Munchenstern, Switzerland  
 Stephan, Christine, Kingersheim, France  
 Seebach, Peter, Inzlingen, Germany, Federal Republic of  
 Riezman, Howard, Biel-Benken, Switzerland  
 PA CIBA-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)  
 PI US 5618690 19970408  
 AI US 1995-462397 19950605 (8)  
 RLI Division of Ser. No. US 1994-328961, filed on 24 Oct 1994, now patented,  
 Pat. No. US 5501975 which is a continuation of Ser. No. US 1992-989260,  
 filed on 11 Dec 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN CNT 1412  
 INCL INCLM: 435/068.100  
 INCLS: 435/069.100; 435/069.700; 435/219.000; 435/223.000  
 NCLM: 435/068.100  
 NCLS: 435/069.100; 435/069.700; 435/219.000; 435/223.000  
 IC (6)  
 ICM: C12P021-06  
 ICS: C12N009-50  
 EXF 435/68.1; 435/69.1; 435/69.7; 435/219; 435/223  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 53 OF 76 USPTAFULL  
 AN 97:3950 USPTAFULL  
 TI Chimera protein comprising an RTX-family cytotoxin and  
 interferon-2 or interferon  
 IN Potter, Andrew, Saskatoon, Canada  
 Campos, Manuel, Lincoln, NE, United States  
 PA Hughes, Huw P. A., Saskatoon, Canada  
 University of Saskatchewan, Saskatoon, Canada  
 Ciba-Geigy Canada Ltd., Mississauga, Canada (non-U.S. corporation)  
 PI US 5594107 19970114  
 AI US 1993-170126 19931220 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-777715, filed on 16 Oct 1991,  
 now patented, Pat. No. US 5273889 which is a continuation-in-part of  
 Ser. No. US 1990-571301, filed on 22 Aug 1990, now patented, Pat. No. US  
 5238823  
 DT Utility



FS Granted  
LN.CNT 1851  
INCL INCLM: 530/350.000 435/069.700; 530/351.000; 530/825.000; 424/192.100;  
INCLM: 424/195.110; 424/197.110; 424/085.100  
NCLM: 530/350.000  
NCLM: 424/085.100; 424/192.100; 424/195.110; 424/197.110; 435/069.500;  
NCLM: 433/069.700; 530/351.000; 530/825.000  
IC [6]  
ICM: C12N015-19  
ICS: A61K039-102  
EXF 530/351: 530/350; 530/324; 530/825; 435/69.5; 435/69.7; 424/192.1;  
424/195.11; 424/197.11; 424/85.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 54 OF 76 USPTAFULL  
AN 96:109073 USPTAFULL  
TI Soluble interferon-gamma receptor fragment  
IN Novick, Daniela, Rehovot, Israel  
PA Rubinstein, Menachem, Givati Shmuel, Israel  
PA Yeda Research and Development, Co., Ltd., Rehovot, Israel (non-U.S. corporation)  
PI US 5578707 19961126  
AI US 1993-16992 19930212 (8)  
RLI Division of Ser. No. US 1990-578826, filed on 7 Sep 1990, now patented,  
Pat. No. US 5221789  
PRAI IL 1989-91562 19890907  
DT Utility  
FS Granted  
LN.CNT 608  
INCL INCLM: 530/395.000  
INCLM: 530/350.000; 530/403.000; 435/069.100; 435/069.700; 424/525.000  
NCLM: 530/395.000  
NCLM: 424/525.000; 435/069.100; 435/069.700; 530/350.000; 530/403.000  
IC [6]  
ICM: C07K014-715  
ICS: A61K038-17  
EXF 514/8; 530/395; 530/350; 530/403; 435/69.1; 435/69.7; 424/525  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 55 OF 76 USPTAFULL  
AN 96:38806 USPTAFULL  
TI Recombinant DNA encoding hybrid immunoglobulins  
IN Capon, Daniel J., San Mateo, CA, United States  
PA Lasky, Laurence A., Sausalito, CA, United States  
PA Genentech, Inc., San Francisco, CA, United States (U.S. corporation)  
PI US 5514582 19960507  
AI US 1994-185670 19940121 (8)  
RLI Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992, now patented, Pat. No. US 5428130 which is a continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now patented, Pat. No. US 5225538 which is a division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5098833  
DT Utility  
FS Granted  
LN.CNT 2644  
INCL INCLM: 435/252.300  
INCLM: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530  
NCLM: 435/252.300  
NCLM: 435/069.700; 435/320.100; 536/023.500; 536/023.520; 536/023.530  
IC [6]  
ICM: C12N015-62

EXF 435/69.7; 435/252.3; 435/320.1; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 56 OF 76 USPTAFULL  
AN 96:29456 USPTAFULL  
TI Rapid immunoselection cloning method  
IN Seed, Brian, Boston, MA, United States  
PA Aruffo, Alejandro, Edmonds, WA, United States  
PA The General Hospital Corporation, Charlestown, MA, United States (U.S. corporation)  
PI US 5506126 19960409  
AI US 1993-139273 19931018 (8)  
RLI Division of Ser. No. US 1992-983647, filed on 1 Dec 1992 which is a continuation-in-part of Ser. No. US 1990-553759, filed on 13 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-379076, filed on 13 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-160416, filed on 25 Feb 1988, now abandoned  
DT Utility  
FS Granted  
LN.CNT 3560  
INCL INCLM: 435/172.300  
INCLM: 435/320.100; 536/024.200  
NCLM: 435/006.000  
NCLM: 435/320.100; 536/024.200  
IC [6]  
ICM: C12N015-10  
EXF 435/172.3; 435/320.1; 536/24.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 57 OF 76 USPTAFULL  
AN 96:24862 USPTAFULL  
TI DNA molecules encoding an ER-located endoprotease  
IN Chaudhuri, Bhabatosh, Munchenstein, Switzerland  
IN Stephan, Christine, Kingersheim, France  
IN Seebach, Peter, Inzlingen, Germany, Federal Republic of  
PA Rietman, Howard, Biel-Benken, Switzerland  
PA Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)  
PI US 5501975 19960326  
AI US 1994-328961 19941024 (8)  
RLI Continuation of Ser. No. US 1992-989260, filed on 11 Dec 1992, now abandoned  
PRAI EP 1991-810984 19911216  
DT Utility  
FS Granted  
LN.CNT 1398  
INCL INCLM: 435/252.300  
INCLM: 536/023.400; 536/023.200; 435/223.000; 435/069.700; 435/069.800; 435/069.900; 435/320.100; 935/014.000; 935/014.000  
NCLM: 435/252.300  
NCLM: 435/069.700; 435/069.800; 435/069.900; 435/223.000; 435/320.100; 536/023.200; 536/023.400  
IC [6]  
ICM: C12N015-63  
EXF 435/223; 435/219; 435/69.7; 435/69.8; 435/69.9; 435/252.3; 435/320.1; 935/10; 935/14; 935/47; 935/48; 935/49; 536/23.2; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 58 OF 76 USPTAFULL  
AN 95:110429 USPTAFULL  
TI Use of the cytokine IP-10 as an anti-tumor agent  
IN Leder, Philip, Chestnut Hill, MA, United States  
IN Luster, Andrew, Wellesley, MA, United States

PA President and Fellows of Harvard College, Cambridge, MA, United States  
(U.S. corporation)  
PI US 5474981 19951212  
AI US 1994-217016 19940323 (8)  
RI Continuation of Ser. No. US 1992-935587, filed on 26 Aug 1992, now abandoned  
DT Utility  
FS Granted  
INCL INCLM: 514/012.000  
INCLM: 514/002.000; 514/908.000; 530/350.000; 530/351.000  
NCLM: 514/012.000  
NCLM: 514/002.000  
NCLM: 514/908.000; 530/350.000; 530/351.000  
ICM: A61K038-16  
ICS: A61K038-17; A61K038-18; C07K014-475  
EXF 514/2; 514/12; 514/908; 530/324; 530/350; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 59 OF 76. USPATFULL  
AN 95:105945 USPATFULL  
TI Antibodies which specifically bind mcl-1 polypeptide  
IN Craig, Ruth W., Hanover, NH, United States  
PA Dartmouth College, Hanover, NH, United States (U.S. corporation)  
PI US 5470955 19951128  
AI US 1993-77848 19930616 (8)  
RI Continuation-in-part of Ser. No. US 1993-12307, filed on 2 Feb 1993, now abandoned  
DT Utility  
FS Granted  
INCL INCLM: 530/387.700  
INCLM: 530/388.800; 530/388.850; 530/389.100; 530/389.700  
NCLM: 530/387.700  
NCLM: 530/388.800; 530/388.850; 530/389.100; 530/389.700  
ICM: C07K016-00  
ICS: C07K016-30  
EXF 530/388.8; 530/389.7; 435/240.27; 435/172.2; 435/70.21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 60 OF 76. USPATFULL  
AN 95:88382 USPATFULL  
TI Expression vector encoding hybrid immunoglobulins  
IN Capon, Daniel J., San Mateo, CA, United States  
PA Genentech Inc., San Francisco, CA, United States (U.S. corporation)  
PI US 5455165 19951003  
AI US 1994-183669 19940121 (8)  
RI Continuation of Ser. No. US 1992-986931, filed on 8 Dec 1992 which is a continuation of Ser. No. US 1991-808122, filed on 16 Dec 1991, now patented, Pat. No. US 5225538 which is a division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 which is a continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5098833  
DT Utility  
FS Granted  
INCL INCLM: 435/064.700  
INCLM: 435/250.300; 435/320.100; 536/023.400  
NCLM: 435/064.700  
NCLM: 435/250.300; 435/320.100; 536/023.400  
ICM: C12N015-62

EXF 435/69.7; 435/252.3; 435/320.1; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 61 OF 76. USPATFULL  
AN 95:84455 USPATFULL  
TI Antagonists of human gamma interferon  
IN Seelig, Gail F., Watchung, NJ, United States  
PA Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)  
PI US 5451658 19950919  
AI WO 9206115.19920416 19930319 (8)  
RI WO 1991-058771 19910925  
WO 1991-058771 19930319 PCT 371 date  
PCT 102(e) date  
RI Continuation-in-part of Ser. No. US 1990-589106, filed on 27 Sep 1990, now abandoned  
DT Utility  
FS Granted  
INCL INCLM: 530/300.000  
INCLM: 530/324.000; 530/326.000; 530/351.000  
NCLM: 530/300.000  
NCLM: 530/324.000; 530/326.000; 530/351.000  
ICM: C07K007-00  
ICS: C07K014-00  
EXF 424/85.8; 435/70.4; 435/172.2; 435/240.27; 435/69.6; 435/69.1; 514/2; 530/351; 530/387.1; 530/387.2; 530/388.1; 530/388.23; 530/300; 530/324; 530/326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 62 OF 76. USPATFULL  
AN 95:84304 USPATFULL  
TI Oncostatin M and novel compositions having anti-neoplastic activity  
IN Shoyab, Mohammed, Seattle, WA, United States  
PA Zarling, Joyce M., Seattle, WA, United States  
Margardt, Hans, Mercer Island, WA, United States  
Hanson, Marcia B., Seattle, WA, United States  
Linsley, Peter S., Seattle, WA, United States  
PA Oncogen Limited Partnership, Seattle, WA, United States (U.S. corporation)  
PI US 5451506 19950919  
AI US 1993-78707 19930616 (8)  
RI Continuation of Ser. No. US 1989-397676, filed on 2 Oct 1989, now abandoned And a continuation-in-part of Ser. No. US 1987-46846, filed on 4 May 1987, now patented, Pat. No. US 5120535 which is a continuation-in-part of Ser. No. US 1986-935283, filed on 26 Nov 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-811235, filed on 20 Dec 1985, now abandoned, said Ser. No. US -397676 which is a division of Ser. No. US 1988-144574, filed on 15 Jan 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-115139, filed on 30 Oct 1987, now abandoned  
DT Utility  
FS Granted  
INCL INCLM: 435/007.230  
INCLM: 435/007.100; 435/007.210; 435/960.000; 530/351.000  
NCLM: 435/007.230  
NCLM: 435/007.100; 435/007.210; 435/960.000; 530/351.000  
ICM: G01N033-74  
ICS: G01N033-68; G01N033-60; C07K013-00  
EXF 435/7.23; 435/7.21; 435/7.1; 435/960; 530/351  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PA	The Regents of the University of California, Oakland, CA, United States	
PI	(U.S. corporation)	19950530
AI	US 5419904	19930226 (8)
RLI	US 1993-26920	
	Continuation-in-part of Ser. No. US 1990-609803, filed on 5 Nov 1990,	
	now abandoned	
DT	Utility	
FS	Granted	
LN CNT	919	
INCL	INCLM: 424/155.100	
	INCLS: 424/142.100; 424/174.100; 435/240.260; 530/387.100; 530/387.700;	
NCL	530/387.900; 530/388.150; 530/388.800	
	NCLM: 424/155.100	
	NCLS: 424/142.100; 424/174.100; 435/244.100; 530/387.100; 530/387.700;	
IC	530/387.900; 530/388.150; 530/388.800	
	[6]	
	ICH: A61K039-395	
EXF	ICS: C12N005-22; C07K016-18; C07K016-30	
	530/387.7; 530/387.9; 530/388.22; 530/388.8; 530/388.15; 424/85.8;	
	424/142.1; 424/174.1; 424/155.1; 435/240.26	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L16	ANSWER 66 OF 76 USPATFULL	
AN	95:1725 USPATFULL	
TI	Nucleic acids encoding type I interferon variants	
II	Marcel, Jacques, Jouy-en-Josas, France	
	Deeryse, Erich, Strasbourg, France	
	Gaye, Pierre, Paris, France	
	Charlier, Madia, Paris, France	
	Charpigny, Gilles, Orleans, France	
	Reinaud, Pierrette, Chailillon, France	
PA	Chaout, Gerard, Paris, France	
	Institut National de la Recherche Agronomique-I.N.R.A., Paris, France	
PI	(non-U.S. corporation)	19950103
AI	US 5378823	
	WO 9209691 19920611	
	US 1992-915707	19920911 (7)
	WO 1991-FR953	19911129
		19920911 PCT 371 date
PRAI	FR 1990-14945	19901129
	FR 1990-14946	PCT 102(e) date
DT	Utility	19901129
FS	Granted	
LN CNT	909	
INCL	INCLM: 536/023.520	
	INCLS: 530/351.000; 435/069.510; 435/320.100; 935/010.000	
NCL	NCLM: 536/023.520	
	NCLS: 435/069.510; 435/320.100; 530/351.000	
IC	[6]	
	ICH: C07H021-04	
EXF	530/407; 530/551; 424/85.4; 424/85.7; 435/69.51; 435/69.7; 435/69.8;	
	435/69.9; 435/172.1; 435/320.1; 435/252.3; 536/23.52; 935/10; 935/37;	
	935/48; 935/69	
CAS	INDEXING IS AVAILABLE FOR THIS PATENT.	
L16	ANSWER 67 OF 76 USPATFULL	
AN	93:106990 USPATFULL	
TI	Gamma-interferon-leukotoxin gene fusions and uses thereof	
II	Potter, Andrew, Saskatoon, Canada	
	Campos, Manuel, Saskatoon, Canada	
	Hughes, Huw P. A., Saskatoon, Canada	
PA	University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)	
	Ciba-Geigy Canada, Ltd., Saskatoon, Canada (non-U.S. corporation)	

PI US 5273889 19931228  
AI US 1991-777715 19911016 (7)  
RLI Continuation-in-part of Ser. No. US 1990-571301, filed on 22 Aug 1990  
DT Utility  
FS Granted  
LN CNT 1727  
INCL INCLM: 435/069.510 435/069.520; 435/069.700; 435/172.300; 435/243.000;  
NCLM: 435/069.500; 435/320.100; 435/811.000; 536/023.100  
NCLM: 435/069.510  
NCLM: 435/069.500; 435/069.520; 435/069.700; 435/243.000; 435/252.300;  
NCLM: 435/320.100; 435/811.000; 536/023.100  
[5]  
ICM: C12N015-23  
ICS: C12N015-19; C07H015-12  
EXF 435/69.5; 435/69.51; 435/69.52; 435/69.7; 435/252.3; 435/243; 435/172.3;  
435/320.1; 435/81; 536/27; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 68 OF 76 USPTAFULL  
AN 93:96042 USPTAFULL  
TI Host transformed with yeast gene and ubiquitin/polypeptide fusions  
IN Liu, Chung-Cheng, Foster City, CA, United States  
Miller, Harvey I., Pleasant Hill, CA, United States  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5262322 19931116  
AI US 1991-694522 19910430 (7)  
RLI Division of Ser. No. US 1988-284281, filed on 14 Dec 1988, now patented, Pat. No. US 5108919 which is a continuation-in-part of Ser. No. US 1988-210909, filed on 24 Jun 1988, now patented, Pat. No. US 5156968  
DT Utility  
FS Granted  
LN CNT 2176  
INCL INCLM: 435/252.330  
NCLM: 435/069.700; 435/172.300; 435/195.000; 435/224.000; 435/252.300;  
NCLM: 435/320.100; 536/023.200; 536/023.400  
NCLM: 435/252.330  
NCLM: 435/069.700; 435/195.000; 435/224.000; 435/252.300; 435/320.100;  
NCLM: 536/023.200; 536/023.400  
[5]  
ICM: C12N001-21  
EXF 435/252.33; 435/252.3; 435/69.7; 435/172.3; 435/195; 435/224; 435/320.1;  
536/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 69 OF 76 USPTAFULL  
AN 93:69752 USPTAFULL  
TI Interleukin-2-leukotoxin gene fusions and uses thereof  
IN Potter, Andrew, Saskatoon, Canada  
Campos, Manuel, Saskatoon, Canada  
Hughes, Huw P. A., Saskatoon, Canada  
Veterinary Infectious Disease Organization, Saskatoon, Canada (non-U.S. corporation)  
PA Ciba-Geigy Canada Ltd, Mississauga, Canada (non-U.S. corporation)  
PI US 5238823 19930824  
AI US 1990-571301 19900822 (7)  
DT Utility  
FS Granted  
LN CNT 1164  
INCL INCLM: 435/069.520  
NCLM: 435/069.100; 435/069.300; 435/069.500; 435/069.700; 435/172.300;  
435/320.100; 435/240.100; 435/243.000; 435/252.300; 536/023.400;  
935/022.000; 935/024.000; 935/027.000; 935/047.000; 935/066.000

NCL INCLM: 435/069.520  
NCLM: 435/069.100; 435/069.300; 435/069.500; 435/069.700; 435/243.000;  
NCLM: 435/320.100; 435/320.100; 435/325.000; 536/023.400  
[5]  
ICM: C12P021-02  
EXF 435/69.1; 435/69.3; 435/69.5; 435/69.52; 435/69.7; 435/172.3; 435/320.1;  
435/243; 435/240.1; 435/252.3; 536/27; 935/22; 935/24; 935/47;  
935/66  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 70 OF 76 USPTAFULL  
AN 93:54852 USPTAFULL  
TI Lymphocyte homing receptor/immunoglobulin fusion proteins  
IN Capon, Daniel J., San Mateo, CA, United States  
Laszky, Laurence A., Sausalito, CA, United States  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5225538 19930706  
AI US 1991-808122 19911216 (7)  
RLI Division of Ser. No. US 1989-440625, filed on 22 Nov 1989, now patented, Pat. No. US 5116964 which is a continuation of Ser. No. US 1989-315015, filed on 23 Feb 1989, now patented, Pat. No. US 5098833  
DT Utility  
FS Granted  
LN CNT 2558  
INCL INCLM: 530/387.300  
NCLM: 435/069.700; 530/388.730  
NCLM: 530/387.300  
NCLM: 424/134.100; 435/069.700; 530/388.730  
[5]  
ICM: C07K013-00  
ICS: C17N015-62  
EXF 435/69.7; 530/387  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 71 OF 76 USPTAFULL  
AN 93:7024 USPTAFULL  
TI Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use thereof  
IN Stepkowski, Zenon, Malvern, PA, United States  
Koprowski, Hilary, Wynnewood, PA, United States  
Thurin, Magdalena, Philadelphia, PA, United States  
The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
PI US 5182192 19930126  
AI US 1990-564115 19900806 (7)  
RLI Division of Ser. No. US 1987-30537, filed on 27 Mar 1987, now patented, Pat. No. US 4971792, issued on 20 Nov 1990  
DT Utility  
FS Granted  
LN CNT 721  
INCL INCLM: 435/007.230  
NCLM: 435/007.900; 435/968.000; 435/007.250; 436/064.000; 436/813.000;  
NCLM: 424/001.100; 424/009.000; 530/391.300  
NCLM: 424/001.490  
NCLM: 424/001.530; 424/009.340; 435/007.230; 435/007.250; 435/007.900;  
435/968.000; 436/064.000; 436/813.000; 530/391.300  
[5]  
ICM: G01N033-574  
EXF 435/7.23; 435/7.25; 435/7.92; 435/960; 435/7.9; 435/968; 436/512;  
436/548; 436/64; 436/813; 530/387; 530/388; 530/828; 530/388.7;  
530/388.8; 530/391.3; 424/1.1; 424/9

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 72 OF 76 USPTAFULL  
92:100931 USPTAFULL  
TI Monoclonal antibodies against lymphoma-associated antigens, hybrid cell  
lines producing these antibodies  
IN Steplewski, Zenon, Malvern, PA, United States  
PA Steplewski, K. Ann, West Chester, PA, United States  
PI The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
AI US 5169775 19921208  
RI US 1990-545590 59900629 (7)  
DT Continuation of Ser. No. US 1987-44285, filed on 3 Apr 1987  
FS Utility  
LN.CNT 1069  
INCL INCLM: 435/240.270  
INCL: 530/388.100; 530/387.300; 530/388.800  
NCL NCLM: 435/344.000  
NCL: 530/387.300; 530/388.100; 530/388.800  
IC [5]  
ICM: C12N005-12  
ICS: C07K015-28; C12P021-08  
EXF 530/387; 530/388.1; 530/388.8; 530/387.3; 435/240.27; 424/85.8; 935/104;  
935/110; 935/107; 935/108  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 73 OF 76 USPTAFULL  
92:42890 USPTAFULL  
TI Hybrid immunoglobulins  
IN Capon, Daniel J., San Mateo, CA, United States  
PA Laskey, Laurence A., Sausalito, CA, United States  
PI Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
AI US 5116964 19920526  
RI US 1989-440625 19891122 (7)  
DT Continuation-in-part of Ser. No. US 1989-315015, filed on 23 Feb 1989  
FS Utility  
LN.CNT 2533  
INCL INCLM: 536/027.000  
INCL: 435/069.700; 435/252.300; 435/320.110; 530/350.000  
NCL NCLM: 536/023.500  
NCL: 424/134.100; 435/069.700; 435/252.300; 435/320.100; 530/350.000;  
530/387.300; 536/023.510; 536/023.530  
IC [5]  
ICM: C07H021-04  
ICS: C12N015-62; C12P021-02  
EXF 435/69.7; 435/172.3; 435/252.3; 435/320; 436/512; 530/350; 530/387;  
536/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 74 OF 76 USPTAFULL  
92:34077 USPTAFULL  
TI DNA sequences encoding yeast ubiquitin hydrolase  
IN Liu, Chung-Cheng, Foster City, CA, United States  
PA Miller, Harvey I., Pleasant Hill, CA, United States  
PI Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
AI US 5108919 19920428  
RI US 1988-284281 19881214 (7)  
DT Continuation-in-part of Ser. No. US 1988-210909, filed on 24 Jun 1988  
FS Utility  
LN.CNT 2214

INCL INCLM: 435/224.000  
INCL: 435/172.300; 435/240.200; 435/252.330; 435/252.300; 435/255.000;  
435/320.100; 536/027.000  
NCL NCLM: 435/224.000  
NCL: 435/252.300; 435/252.330; 435/254.210; 435/320.100;  
435/365.000; 536/023.200; 536/023.600  
IC [5]  
ICM: C12N009-60  
ICS: C12N015-00; C07H015-12  
EXF 435/91; 435/195; 435/224; 435/240.1; 435/252.3; 435/252.33; 435/255;  
435/300; 536/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 75 OF 76 USPTAFULL  
90:89116 USPTAFULL  
TI Monoclonal antibodies against glycolipid antigens  
IN Steplewski, Zenon, Malvern, PA, United States  
PA Koprowski, Hilary, Wynnewood, PA, United States  
PI Thurnin, Magdalena, Philadelphia, PA, United States  
AI The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
RI US 4971792 19901120  
DT US 1987-30537 19870327 (7)  
FS Utility  
LN.CNT 700  
INCL INCLM: 424/085.910  
INCL: 530/380.000; 530/381.000; 530/387.000; 530/388.000; 530/389.000;  
530/391.000; 530/395.000; 530/806.000; 530/808.000; 530/828.000;  
424/093.000; 435/240.200; 435/240.260; 435/240.270  
NCL NCLM: 424/001.490  
NCL: 424/085.500; 424/085.700; 424/093.710; 424/137.100; 424/178.100;  
424/183.100; 530/380.000; 530/381.000; 530/387.500; 530/388.700;  
530/388.850; 530/391.300; 530/391.700; 530/395.000; 530/806.000;  
530/808.000; 530/828.000  
IC [5]  
ICM: A61K039-395  
ICS: C07K015-28  
EXF 429/85; 429/86; 429/87; 429/85.8; 429/85.91; 429/93; 530/387; 530/809;  
530/828; 530/808; 435/240.26; 435/240.27; 935/103  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 76 OF 76 USPTAFULL  
89:58819 USPTAFULL  
TI Monoclonal antibodies against melanoma-associated antigens and hybrid  
cell lines producing these antibodies  
IN Thurnin, Jan, Philadelphia, PA, United States  
PA Koprowski, Hilary, Wynnewood, PA, United States  
RI Herlyn, Weenhard, Wynnewood, PA, United States  
PI Steplewski, Zenon, Malvern, PA, United States  
PA The Wistar Institute, Philadelphia, PA, United States (U.S. corporation)  
AI US 4849509 19890718  
RI US 1987-16902 19870220 (7)  
DT Utility  
FS Utility  
LN.CNT 829  
INCL INCLM: 530/387.000  
INCL: 530/389.000; 530/806.000; 530/828.000; 424/085.800; 435/068.000;  
435/172.200; 435/172.300; 435/240.270  
NCL NCLM: 530/388.200  
NCL: 424/137.100; 424/156.100; 435/070.210; 435/329.000; 435/344.100;  
530/388.850; 530/806.000; 530/828.000; 530/861.000  
IC [4]  
ICM: A61K039-395  
ICS: C12N015-00; C07K015-04

EXE 530/387; 530/388; 530/389; 530/391; 530/806; 530/828; 424/85; 424/85.8;  
435/68; 435/172.2; 435/240.27; 435/240.26  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 114 1-8

L14 ANSWER 1 OF 8 USPTAFULL  
AN 199639396 CANCERLIT  
DN 98639396  
TI Immunomodulatory fusion proteins for cancer  
therapy (meeting abstract).  
AU Zhao L; Chace D; Grosmaire L; Ledbetter J; Siegal C B; Fell H P  
CS BMS Pharmaceutical Research Institute, Bristol-Myers Squibb, Seattle, WA  
98121.  
SO Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A2396.  
ISSN: 0197-016X.  
DT (MEETING ABSTRACTS)  
FS ICDB  
LA English  
EM 199801

L14 ANSWER 2 OF 8 USPTAFULL  
AN 1999.117645 USPTAFULL  
TI Products and processes for regulation of gene recombination  
DN Dreyfus, David H., Denver, CO, United States  
TI Gelfand, Erwin W., Englewood, CO, United States  
PA National Jewish Medical and Research Center, Denver, CO, United States  
(U.S. corporation)  
PI US 5959074 19990928  
AI US 1997-807332 19970228 (8)  
PRAI US 1996-12616P 19960301 (60)  
DT US 1996-23064P 19960802 (60)  
FS Utility  
LN.CNT 2196  
INCL INCLM: 530/300.000  
NCL INCLM: 530/324.000  
NCLM: 530/300.000  
NCLM: 530/324.000  
IC (6)  
ICM: C07K014-00  
EXF 530/300; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329; 530/330;  
530/350  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 8 USPTAFULL  
AN 1999.72572 USPTAFULL  
TI DNA transcription unit vaccines that protect against avian influenza  
DN viruses and methods of use thereof  
AU Webster, Robert, Memphis, TN, United States  
PA St. Jude Children's Research Hospital, Memphis, TN, United States (U.S.  
corporation)  
PI US 5916879 19990629  
AI US 1996-747286 19961112 (8)  
DT Utility  
FS Granted  
LN.CNT 1891  
INCL INCLM: 514/044.000  
INCLM: 435/459.000; 435/320.100; 536/023.720; 424/209.100; 424/210.100;  
424/816.000  
NCL INCLM: 514/044.000  
NCLM: 424/209.100; 424/210.100; 424/816.000; 435/320.100; 435/459.000;  
536/023.720  
IC (6)  
ICM: A61K048-00  
ICS: C12N015-87; C12N015-44  
EXF 536/23.72; 514/44; 424/209.1; 424/816; 424/199.1; 424/210.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 8 USPTAFULL  
AN 1998.134627 USPTAFULL  
TI Yeast-based delivery vehicles  
DN Duke, Richard C., Denver, CO, United States  
TI Frank, Rexham S., Wellington, CO, United States  
PA University Technology Corporation, Boulder, CO, United States (U.S.  
corporation)  
PI US 5830463 19981103  
AI US 1994-340185 19941115 (8)  
RUI Continuation-in-part of Ser. No. US 1993-88322, filed on 7 Jul 1993, now  
patented, Pat. No. US 5413914  
DT Utility  
FS Granted  
LN.CNT 1929  
INCL INCLM: 424/093.510  
INCLM: 424/093.500; 424/093.200; 435/320.100; 435/375.000; 435/172.300;  
435/069.100  
NCL INCLM: 424/093.510  
NCLM: 424/093.200; 424/093.500; 435/069.100; 435/320.100; 435/375.000  
IC (6)  
ICS: C12N015-09; A61K048-00  
EXF 435/320.1; 435/240.2; 435/6; 435/7.1; 435/172.3; 435/7.2; 435/7.31;  
514/44; 935/62; 935/52; 935/55; 935/56; 935/57; 935/34; 935/32;  
424/93.1; 424/93.2; 424/93.21; 424/93.51; 424/93.5; 536/23.74  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 8 USPTAFULL  
AN 1998.108036 USPTAFULL  
TI Recombinant canine herpesviruses  
DN Haanes, Elizabeth J., Berthoud, CO, United States  
TI Frank, Rexham S., Wellington, CO, United States  
PA Hesk Corporation, Ft. Collins, CO, United States (U.S. corporation)  
PI US 5804197 19980908  
AI US 1996-680726 19960712 (8)  
RUI Continuation-in-part of Ser. No. US 1996-602010, filed on 15 Feb 1996  
DT Utility  
FS Granted  
LN.CNT 5536  
INCL INCLM: 424/229.100  
INCLM: 424/199.100; 435/235.100; 435/320.100  
NCL INCLM: 424/229.100  
NCLM: 424/199.100; 435/235.100; 435/320.100  
IC (6)  
ICM: A61K039-245  
EXF 424/229.1; 424/199.1; 435/235.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 8 USPTAFULL  
AN 1998.57716 USPTAFULL  
TI Aptamers specific for biomolecules and methods of making  
DN Griffin, Linda, Atherton, CA, United States  
TI Albrecht, Glenn, Redwood City, CA, United States  
PA Latham, John, Palo Alto, CA, United States  
DN Leung, Lawrence, Hillsborough, CA, United States  
PA Vermaas, Eric, Oakland, CA, United States  
TOOLE, John J., Burlingame, CA, United States  
PI Gilead Sciences, Inc., Foster City, CA, United States (U.S. corporation)  
AI US 5756291 19980526  
US 1995-484192 19950607 (8)  
RUI Continuation of Ser. No. US 1992-934387, filed on 21 Aug 1992, now

DT abandoned  
FS Utility  
LN.CNT 8242  
INCL INCLM: 435/006.000; 530/413.000; 935/077.000; 935/078.000  
NCL INCLM: 536/023.100; 536/023.100  
NCLM: 435/006.000  
NCLS: 530/413.000; 536/023.100  
IC [6]  
ICM: C120001-68  
ICS: C07K001-14; C07H021-02  
435/6; 935/77; 935/78; 530/413; 536/23.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 7 OF 8 USPATFULL  
AN 1998:54490 USPATFULL  
TI Recombinant canine herpesviruses  
IN Haanes, Elizabeth J., Boulder, CO, United States  
Frank, Rexann S., Wellington, CO, United States  
PA Heeka Corporation, Ft. Collins, CO, United States (U.S. corporation)  
PI US 5793235  
AI US 1996-602010 19980519  
DT Utility 19960215 (8)  
FS Granted

LN.CNT 3143  
INCL INCLM: 424/229.100  
INCLM: 424/147.100; 435/235.100; 530/388.300; 530/395.000  
NCL INCLM: 424/229.100  
NCLS: 424/147.100; 435/235.100; 530/388.300; 530/395.000  
IC [6]  
ICM: A61K039-245  
ICS: C12N007-01; C07K001-00; C12P021-02  
424/229.1; 424/147.1; 435/235.1; 530/388.3; 530/395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 8 USPATFULL  
AN 1998:36732 USPATFULL  
TI Polynucleotide tuberculosis vaccine  
IN Content, Jean, Rhode-Saint-Genese, Belgium  
Huygen, Kris, Brussels, Belgium  
Liu, Margaret A., Rosemont, PA, United States  
Montgomery, Donna, Chalfont, PA, United States  
Ulmer, Jeffrey, Chalfont, PA, United States  
Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PA N. V. Innogenetics S.A., Ghent, Belgium (non-U.S. corporation)  
PI US 5736524 19980407  
AI US 1994-338992 19941114 (8)  
DT Utility  
FS Granted

LN.CNT 1346  
INCL INCLM: 514/044.000  
INCLM: 435/006.000; 435/069.100; 435/172.300; 435/375.000; 435/320.100;  
935/062.000; 935/056.000; 935/034.000; 935/065.000  
NCL INCLM: 514/044.000  
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/375.000  
IC [6]  
ICM: A61K048-00  
ICS: C07H021-00; C12N015-79; C12N015-63  
435/320.1; 435/6; 435/69.1; 435/172.3; 435/243; 435/252.1; 514/44;  
935/62; 935/65; 935/66; 935/70; 935/71; 935/73; 935/34; 935/72  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.



=> s 19 and treat?  
L18 2 L9 AND TREAT?

=> d 118 1-2

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:713568 CAPLUS:  
DN 135:268188  
TR Methods of making chimeric protein hPRLA/IL-2 and uses as a  
bi-functional cancer treatment agent  
IN Chen, Wen Y.; Wagner, Thomas E.  
PA Greenville Hospital System, USA  
SO PCT Int. Appl., 47 pp.  
DT Patent  
LA English  
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001070985	A2	20010927	WO 2001-US9284	20010323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2000-191457P P 20000323

L18 ANSWER 2 OF 2 USPTFULL  
AN 2001:194148 USPTFULL  
TI PROLACTIN ANTAGONISTS AND USES THEREOF  
IN WALKER, AIMEE M., RIVERSIDE, CA, United States  
PI US 2001036662 A1 20011101  
AI US 1998-65330 A1 19980423 (9)  
WO 1997-US1435 19970130

DT Utility  
ES APPLICATION  
LN.CNT 1083  
INCL INCLM: 435/320.100  
INCLS: 536/023.500  
NCL NCLM: 435/320.100  
NCLS: 536/023.500  
IC [77]  
ICM: C12N015-63  
ICS: C07H021-04; C12N015-00; C12N015-74; C12N015-70; C12N015-09

CAS INDEXING IS AVAILABLE FOR THIS PATENT.